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AP-1   Activator protein 1 
APC    Antigen presenting cell 
BATF    Basic leucine zipper transcription factor, ATF-like 
BCL6    B cell leukemia/lymphoma 6 
CCR6    Chemokine (C-C motif) receptor 6 
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CD69    Cluster differentiation 69 
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DSS    Dextran sulfate sodium 
EAE    Experimental autoimmune encephalomyelitis 
ELISA    Enzyme linked immunosorbent assay 
Foxp3    Forkhead box P3 
GATA3   GATA binding protein 3 
GM-CSF   Granulocyte-macrophage colony-stimulating-factor 
IBD    Inflammatory bowel disease 
IFN-γ    Interferon gamma 
IL-17    Interleukin 17 
IL-23R   Interleukin-23 receptor 
IRF    Interferon regulatory factor 
iTreg    Inducible regulatory T cell  
JAK    Janus kinase 
LPL    lamina propria lymph node 
LPS    Lipopolysaccharides 
MAF    Avian musculoaponeurotic fibrosarcoma oncogene homolog 
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MLN    Mesenteric lymph node 
MOG35-55   Myelin oligodendrocyte glycoprotein, residue 35-55 
MS    Multiple sclerosis  
NFAT    Nuclear factor of activated T cells 
NF-κB    Nuclear factor of kappa light polypeptide gene enhancer in B cells 
nTreg    Natural regulatory T cell 
PMA    Phorbol 12-myristate 13-acetate  
PTX    Pertussis toxin 
Rag2    Recombination activating gene 2 
RORα    RAR-related orphan receptor alpha 
RORγt    RAR-related orphan receptor gamma T 
RUNX1   Runt-related transcription factor 1 
SH2    Src homology 2 
SOCS    Suppressor of cytokine signaling 
STAT    Signal transducer and activator of transcription 
T-bet    T-cell-specific T-box transcription factor 
TCR    T cell receptor 
TF    Transcription factor 
TFH    Follicular B helper T cell 
TGF-β    Transforming growth factor, beta 
TH1    Type 1 helper T cell 
TH17    IL-17-producing helper T cell 
TH2    Type 2 helper T cell 
TH9    IL-9-producing helper T cell 
TLR    Toll-like receptor 
TNF-α    Tumor necrosis factor, alpha 
Treg    Regulatory T cell 
UC    Ulcerative colitis 
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SUMMARY 
CD4+ T cells play a crucial role in host defense against infectious pathogens, but the 
aberrant T cell responses could result in autoimmune diseases and inflammatory 
disorders. TH1 and TH17 cells have been thought to mediate inflammation in both 
peripheral tissues and central nervous systems. This thesis explores the role of STAT5 
in the regulation of CD4+ helper T cell lineage commitment and T cell-mediated 
autoimmune diseases.  
First, we showed that IL-2 suppressed naïve CD4+ T cell differentiation into TH17 
cells. The deletion of Stat5 abrogated most suppressive effect of IL-2, suggesting 
STAT5 is a negative regulator in TH17 differentiation. Furthermore, IRF8 was 
identified as a potential target of IL-2-STAT5 signaling that mediated the suppression 
of TH17 differentiation. Second, we reported a surprising finding that loss of STAT5 
in CD4+ T cells suppressed the development of experimental autoimmune 
encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS), despite the 
antagonistic role of STAT5 in TH17 differentiation. The resistance to EAE was 
accompanied with reduced neuroinflammation in the central nerve system of 
Stat5-deficient mice. We demonstrated that Stat5 mutant mice had no defect in 
peripheral immune response to MOG35-55/CFA immunization and Stat5-deficient 
autoreactive CD4+ T cells were able to migrate to the CNS. Moreover, TH1 and TH17 
generation was enhanced in the absence of STAT5, whereas they were unable to 
induce neuroinflammation. It is likely that STAT5 induces a specific pathogenic 
mediator required for autoimmune neuroinflammation. Third, we found GM-CSF 
induction was diminished in Stat5-deficient autoreactive CD4+ T cells. We have 
further characterized IL-7 as the signal, which induced GM-CSF expression through 
STAT5 independent of IL-23 and IL-1β signaling. Intriguingly, this 
IL-7-STAT5-GM-CSF axis is not required for T cell-mediated colitis. Our findings 
suggest STAT5 is required for a new GM-CSF-expressing TH cell subset, which is 
specific for autoimmune neuroinflammation. Fourth, in contrast to previous reports 
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that IL-23 regulates GM-CSF expression in encephalitogenic TH17 cells, we 
characterized that IL-7/STAT5-induced GM-CSF expression from naïve T cells was 
independent of IL-23. We presented data showing that the differentiation of 
GM-CSF-expressing TH cells was suppressed by either TH1-polarizing condition or 
TH17-polarizing condition. In addition, IL-6-STAT3 signaling which is crucial for 
TH17 differentiation strongly suppressed the differentiation of GM-CSF-expressing 
TH cells. These data argue that GM-CSF-expressing TH cell population is a new 
subset distinct from TH1 and TH17. We further demonstrated that IL-7-STAT5 
signaling programed the differentiation of the new subset. Taken together, our study 
discovers a novel TH subset specifically required for autoimmune neuroinflammation. 
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CHAPTER 1 INTRODUCTION 
 
1.1 Overview 
It has been well known that the immune system is essential for keeping humans 
healthy and preventing them against infectious diseases. The process that the immune 
system recognizes and erases foreign invaders is termed immune response. Immune 
responses are strictly controlled to prevent the occurrence of immune disorders. The 
dysregulation of immune responses results in autoimmune diseases, inflammatory 
diseases and cancers. The causal reason behind the undesirable response of immune 
systems to self-antigen remains largely unknown. The current hypothesis is that 
environmental factors (substances or microorganisms) trigger the immune response, 
which subsequently results in the aberrant response to body substances or tissues 
especially in individuals bearing mutant genes in their genome susceptible to 
autoimmune diseases. Autoimmune diseases may cause body tissue destruction, 
abnormal organ development and organ dysfunction, resulting in illness or even death. 
Attempts have been made to treat autoimmune diseases clinically. However, current 
medicines, so called immunosuppressive medicines, are usually prescribed to reduce 
immune responses rather than targeting causal factors. Therefore, understanding the 
pathogenesis of autoimmune diseases is very helpful to improve the clinical treatment 
of such diseases.  
One subset of autoimmune diseases, such as multiple sclerosis, inflammatory bowel 
disease, and rheumatoid arthritis, is mediated by autoreactive helper T cells. Normal 
individuals preserve central tolerance and peripheral tolerance to prevent the 
generation of autoreactive T cells. In the process of central tolerance, naïve 
lymphocytes undergo positive selection to eliminate T cell precursors that exhibit any 
affinity to self-antigen. Peripheral tolerance is important as it suppresses the immune 
response caused by autoreactive T cells that are escaped from central tolerance. CD4+ 
regulatory T cells are the major suppressive cells in peripheral tolerance. Breakdown 
of one or more of T cell-mediated immune tolerance is a common feature of 
autoimmune diseases. In general, cytokine imbalance is an accomplice in the 
induction and progression of autoimmune diseases. Usually the cytokine imbalance 
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occurs with increased proinflammatory cytokines and reduced anti-inflammatory 
cytokines. The production of inflammatory cytokines is greatly attributed to enhanced 
activity of CD4+ T cells. In particular, three types of CD4+ T cells are important in 
this regard: TH1, TH2 and TH17. Signaling transduction regulates CD4+ T cell 
differentiation and activity, therefore, is important in the genesis of autoimmune 
diseases. In the following parts of Chapter 1, a detailed review of studies on 
JAK-STAT signaling pathway, CD4+ T cell lineage commitment, TH17 cell 
differentiation and two types of autoimmune diseases will be presented.  
 
1.2 JAK-STAT signaling pathway 
The study on the action of interferons (IFNs) uncovered the JAK (Janus 
kinase)-STAT (signal transducers and activators of transcription) pathway. JAK1 was 
identified as the first member of JAK family required for the cellular response to type 
I interferons (Wilks, 1989).  Shortly after that, components of interferon-stimulated 
response elements (ISGF-3) were purified and identified as subunits 113, 91, 84 and 
48 kDa (Fu et al., 1990), which were later cloned and designated STAT1 (isoform a 
and b), STAT2 and IRF9 (Fu et al., 1992; Veals et al., 1992). Up to date, four JAKs 
(JAK1, JAK2, JAK3 and Tyk2) and seven STATs (STAT1, STAT2, STAT3, STAT4, 
STAT5a, STAT5b and STAT6) have been identified in mammals (Stark and Darnell, 
2012).  
 
Figure 1 Domain structures of JAK and STAT. 
JAKs have FERM, SH2, pseudokinase and kinase domains. FERM and SH2 regulate 
kinase activity. STATs comprise amino terminal, coiled-coil, DAB, linker, SH2 and 
transactivation domains.  
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JAKs was named by analog to the double-faced Roman god Janus, because of one 
recognizable kinase domain and one related but enzymatically inactive domain (Wilks, 
1989). Four members of JAK family are characterized by shared sequence features: a 
carboxyl-terminal catalytic domain, an adjacent pseudokinase domain, a Src 
homology 2 (SH2) domain and a FERM domain at amino-terminal (Fig. 1). The 
kinase domain catalyzes the phosphorylation on specific tyrosine residue of cytokine 
receptors, JAKs and STATs (Argetsinger et al., 1993; Muller et al., 1993; Velazquez 
et al., 1992). The pseudokinase domain is essential for regulating JAK kinase activity 
(Chen et al., 2000; Saharinen et al., 2000). The FERM domain mediates receptor 
interaction and modulates kinase activity (Hilkens et al., 2001; Zhou et al., 2001).  
STATs are designated due to the dual functions as both signal transducers and 
transcription activators. STATs are 750 to 850 amino acids in length and consist of 
six domains: amino terminal, coiled-coil, DNA binding domain (DBD), linker, SH2 
and transcriptional activation domain (TAD) (Fig. 1). SH2 domain is the feature of 
STATs and essential for STAT recruitment to receptors and dimerization. TAD, when 
phosphorylated on serine residue, promotes transcriptional activity and selective gene 
expression (Decker and Kovarik, 2000; Kovarik et al., 2001). The DBD portion of 
STAT dimer forms a barrel with an immunoglobulin fold responsible for DNA 
binding. The coiled-coil domain represents extensive possibilities for protein 
interactions. The function of linker is unknown. The amino domain is important for 
STAT tetramerization and transcriptional regulation (John et al., 1999; Xu et al., 
1996).  
The JAK-STAT pathway serves as a paradigm demonstrating how extracellular 
signals can be directly conveyed to gene expression (Levy and Darnell, 2002b). The 
binding of interferons or cytokines to their receptors on the cell surface results in 
receptor dimerization or oligomerization, which subsequently leads to JAK apposition 
and activation by transphosphorylation on tyrosine residues. Activated JAKs in turn 
phosphorylate the cytoplasmic domains of the receptors, providing docking sites for 
STATs. The STAT proteins are then recruited and bind via SH2-phosphotyrosine 
interactions. Upon the recruitment, STATs are phosphorylated by JAKs on a single 
tyrosine residue (around residue 700), permitting the STAT dimerization and 
translocation into the nucleus where STAT dimers bind DNA and regulate gene 
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transcription. The JAK-STAT pathway is regulated from several aspects. A family of 
SH2-containing proteins, named suppressor of cytokine signaling (SOCS), are known 
to activated by JAK-STAT pathway and in turn inhibit signaling by inhibiting JAKs, 
by blocking STAT recruitment and by promoting degradation of receptor/JAK 
complex. Several tyrosine phosphatases such as SHP-1 and PTP1b mediate the 
dephosphorylation on tyrosine residues of JAKs and receptors, thus inhibit 
JAK-STAT pathway (O'Shea et al., 2002). Besides tyrosine phosphorylation of 
residue 700, the activation of STATs is regulated through multiple posttranslational 
modifications, such as serine phosphorylation, arginine methylation, lysine 
methylation and SUMOylation (Levy and Darnell, 2002a; Stark and Darnell, 2012).  
The JAK-STAT pathway is well established from the studies on IFN responses. In the 
past two decades, a variety of cytokines and growth factors have been shown to 
induce JAK-STAT activation, indicating their wide biological functions (Akira, 1999). 
The primary roles of JAK and STAT proteins are defined by gene targeting in mice 
(summarized in Table 1). It is worth noting that STATs are not exclusively activated 
by JAKs but also activated by several receptor tyrosine kinases, for example EGFR 
and PDGFR (Vignais et al., 1996), and by G-protein-coupled receptors, for example, 
angiotensin II receptor (Marrero et al., 1995).  
STAT3 plays a plethora of biological activities in response to various cytokines and 
growth factors. STAT3 is originally identified as the downstream molecule activated 
by IL-6 (Interleukin 6). The binding of IL-6 to its receptor causes dimerization of 
IL-6R and Gp130, which leads to JAK1 apposition and activation. Activated JAK1 
phosphorylates Gp130 at several tyrosine residues, providing docking sites for 
STAT3. STAT3 proteins are then recruited and subsequently get phosphorylated at 
tyrosine 704 by JAK1. Phosphorylated STAT3 proteins form dimers and translocate 
to the nucleus, where they bind DNA and activate gene expression, for example IL-17 
expression in TH17 cells. STAT3 activation also induces expression of a number of 
inhibitors including SOCS3. By now, it is known that a variety of cytokines as well as 
growth factors can activate STAT3, including IL-10, IL-21, IL-22, IL-23, OSM, LIF, 
CNTF, Leptin and EGF, etc (Yu et al., 2009b). The biological functions of STAT3 are 
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closely related to their roles in transmitting different cytokine and growth factor 
signals as shown in Table 1.  
STAT3 has two isoforms generated by alternative splicing of Stat3 gene transcript: 
the full length STAT3α (86~92 kDa) and C-terminal truncated STAT3β (79~82 kDa). 
There are only limited reports focusing on their redundant and/or non-redundant 
functions. STAT3β lacks transactivation (TAD) domain and is generally considered 
as a dominant negative factor. However, evidence from genetically mutant mouse of 
either isoform shows that STAT3β is not a dominant negative factor in vivo. STAT3β 
can also induce expression of certain STAT3 target genes and rescue the embryonic 
lethality caused by Stat3 gene deletion. Nevertheless, STAT3α plays unique roles 
such as in transmitting IL-6 and IL-10 signaling in macrophage (Maritano et al., 
2004). For another example, STAT3α and STAT3β isoforms have distinct 
intracellular dynamics in response to cytokine stimulation, with STAT3β exhibiting 
prolonged retention in the nucleus and reduced intranuclear mobility (Huang et al., 
2007).  
STAT5 has pleiotropic functions regulating lymphopoiesis, erythropoiesis, body 
growth and mammary gland development, due to its crucial roles in transmitting 
IL7/IL-3/IL-2, EPO, growth hormone, and prolactin signaling. STAT5 shares the 
similar signaling transduction pathways as STAT3, involving JAK1, JAK2 and JAK3 
depending on the receptors. STAT5 includes two isoforms, STAT5a (94 kDa) and 
STAT5b (92 kDa), encoded by two closely related genes (Stat5a and Stat5b) with ~96% 
homology in mammals. For many types of cells, STAT5a and STAT5b have some 
redundant functions, but deletion of individual genes in mice reveals their unique 
biological functions. Stat5a-deletion mice show impaired development of mammary 
gland due to unresponsiveness to prolactin, even though these mice appear normally 
(Liu et al., 1997). On the other hand, Stat5b deletion leads to sexually dimorphic 
growth retardation because of its critical role in mediating growth hormone signaling 
(Udy et al., 1997). Mice with individual Stat5a or Stat5b deletion are viable. The 
initial gene targeting strategy for generating Stat5a/b-double knockout mice resulted 
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in N-terminal truncated STAT5a/b proteins (STAT5ΔN) with partial functions, which 
leads to the underestimation of their importance (Teglund et al., 1998). However, the 
complete deletion of Stat5a/b locus results in more than 99% perinatal lethality, with 
only a few extremely runted and anemic survivals (Cui et al., 2004). 
With respect to lymphocyte development, deletion of individual Stat5a or Stat5b has 
relatively modest consequences, suggesting their functional redundancy (Imada et al., 
1998; Kelly et al., 2003). The analysis of the few survivors in Stat5a/b complete 
knockout mice validates the crucial roles of STAT5a/b in lymphopoiesis of both T 
and B lineages. The importance of STAT5a/b in T cell biology is also demonstrated 
by conditional knockout of Stat5a/b locus in double positive stage of T cell 
development, which results in a marked reduction of peripheral CD8+ T cells 
(Burchill et al., 2007; Yao et al., 2006). The role of STAT5 in CD4+ T cell 
development and differentiation is discussed in Chapter 1.3. STAT5 refers to 
STAT5a/b proteins and Stat5 refers to Stat5a/b locus in the following chapters by 
default.   
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Table 1 JAK-STAT functions revealed by gene targeting in mice. 
Gene Phenotype of knockout mice References 
Jak1 Perinatal lethality; lymphopoiesis; impaired 
immune responses due to failure of multiple 
cytokines 
(Rodig et al., 1998) 
Jak2 Embryonic lethality due to the absence of 
erythropoiesis; impaired immune responses due 
to failure of multiple cytokines         
(Neubauer et al., 
1998; Parganas et 
al., 1998) 
Jak3 severe combined immunodeficiency disease 
(SCID) due to failure of cytokine signaling 
through γc receptors 
(Nosaka et al., 1995; 
Park et al., 1995; 
Thomis et al., 1995) 
Tyk2 Partially impaired responses to type I IFNs (Karaghiosoff et al., 
2000; Shimoda et 
al., 2000) 
Stat1 Defective responses to IFNs; highly susceptible 
to microbial and viral infections; increased 
susceptible to tumor genesis; impaired growth 
control 
(Durbin et al., 1996; 
Meraz et al., 1996; 
Shankaran et al., 
2001) 
Stat2  Impaired responses to type I IFNs; susceptible to 
viral infection 
(Park et al., 2000) 
Stat3 Embryonic lethality; a variety of malfunctions 
demonstrated by tissue-specific deletion of 
STAT3 such as impaired cell survival and 
aberrant immune response ; impaired IL-6 
responsiveness; resistant to several types of 
autoimmune diseases 
(Durant et al., 2010; 
Jacoby et al., 2003; 
Kano et al., 2003; 
Liu et al., 2008; 
Takeda et al., 1999; 
Takeda et al., 1997; 
Welte et al., 2003) 
Stat4 Impaired IL-12 responsiveness and TH1 
differentiation; resistant to several types of 
autoimmune diseases 
(Chitnis et al., 2001; 
Kaplan et al., 
1996b; Thierfelder 
et al., 1996; Wurster 
et al., 2000) 
Stat5a Impaired responsiveness to prolactin and 
mammary gland development 
(Liu et al., 1997) 
Stat5b Growth retardation due to loss of growth 
hormone responsiveness  
(Udy et al., 1997) 
Stat5a/b Perinatal lethality; severe anemia; loss of 
immune tolerance 
(Cui et al., 2004; 
Snow et al., 2003) 
Stat6 Impaired IL-4 responsiveness and TH2 
differentiation; impaired expulsion of helminthic 
infection; enhanced tumor immunity 
(Kaplan et al., 
1996a; 
Ostrand-Rosenberg 
et al., 2000; 
Shimoda et al., 
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1.3 CD4+ T cell lineage commitment 
CD4+ helper T (TH) cells play a crucial role in host defense against various pathogens 
by orchestrating adaptive immune responses. Upon T-cell receptor (TCR) activation 
by cognate antigen, naïve CD4+ T cells are committed to differentiate into at least five 
major subsets: TH1, TH2, TH17, iTreg and TFH, which are modulated by cytokine 
milieus. Environmental cytokines activate or induce lineage-specifying transcription 
factors, which further establish and maintain the regulatory networks and unique 
cytokine productions during the process of TH cell lineage commitment (Fig. 2). 
 
 
Figure 2 A classic view of CD4+ T cell lineage commitment. 
[Modified from (O'Shea and Paul, 2010)]  
TCR activation by cognate antigen presented by APCs differentiates naïve CD4+ T 
cells into different lineages dependent on the cytokine milieus. STAT proteins 
transmit cytokine signals and determine the induction of lineage-specifying 
transcription factors, which establish and maintain lineage specificity. Different 
lineages produce a unique profile of cytokines.  
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The classic view of CD4+ T cells subsets, consisting of TH1 （Type1 helper T cell) 
and TH2 (Type 2 helper T cells), was first described by Mossman and Coffman 
(Mosmann et al., 1986). At the time of antigen encounter, IL-12 activates STAT4, 
which is responsible for upregulating the expression of master regulator T-bet, 
T-cell-specific T-box transcription factor (Kaplan et al., 1996b; Thierfelder et al., 
1996; Yang et al., 2007b). STAT4 and T-bet then bind to Ifng (Interferon γ) locus and 
activate its expression, which in turn activates STAT1 and reinforces the expression 
of T-bet (Afkarian et al., 2002; Lighvani et al., 2001; Szabo et al., 2002). Together 
with other regulatory molecules (Zhu and Paul, 2010), STAT4 and T-bet promote TH1 
lineage commitment and inhibit TH2 differentiation. TH2 differentiation is initiated by 
TCR activation in the presence of IL-4. STAT6 activated by IL-4 together with 
TCR-induced transcription factors induce GATA3 expression, which is the master 
regulator of TH2 (Kaplan et al., 1996a; Shimoda et al., 1996; Takeda et al., 1996).  
GATA3 and STAT6 together induce the transcription of Il4, Il5 and Il13 to form a 
positive feed-back loop (Ansel et al., 2006). Therefore, TH2 lineage commitment is 
stabilized by IL-4-STAT6-GATA3-IL-4 loop. Furthermore, STAT6 and GATA3 
mediate the antagonism of IFN-γ expression and TH1 differentiation (Ansel et al., 
2006).  
TH1 and TH2 cells have distinct functions closely related to their unique cytokine 
production: TH1 cells predominantly produce IFN-γ and protect host against 
intracellular viral and bacterial infection; TH2 cells potently produce IL-4, IL-5 and 
IL-13, crucial for expelling extracellular parasites. Besides their critical functions in 
host defense against foreign pathogens, both types of TH cells are associated with 
certain types of inflammatory and autoimmune diseases. Asthma is considered as a 
TH2-associated inflammatory disease, in which TH2 cytokines (IL-4, IL-5 and IL-13) 
are thought to contribute to the disease pathology (Lloyd and Hessel, 2010). TH1 cells 
are considered to be associated with multiple sclerosis, inflammatory bowel disease 
and rheumatoid arthritis.  
However, the TH1/TH2 paradigm fails to explain some discrepancies observed in the 
pathological study of Experimental Autoimmune Encephalomyelitis (EAE). For 
instance, deletion of IFN-γ or IL-12p35 leads to exacerbated disease development in 
EAE mice, while IL-12p40-deficienct mice are resistant to EAE (Becher et al., 2002; 
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Chu et al., 2000; Gran et al., 2002). IL-12 is a heterodimeric cytokine consisting of a 
40 kDa subunit (IL-12p40) and a 35 kDa subunit (IL-12p35). The realization that 
IL-12p40 subunit is double used by both IL-12 and IL-23, draws the attention to the 
pathological role of IL-23 in autoimmune diseases. Subsequent studies using rodent 
models of autoimmune diseases show that IL-23 rather than IL-12 is crucial for 
disease development (Cua et al., 2003; Murphy et al., 2003). These studies also show 
that IL-23 is not important for IFN-γ expression but required for IL-17 expression, 
which indicates that IL-17 expression in CD4+ T cells is regulated in a way distinct 
from IFN-γ. Shortly after these findings, IL-23 was further reported to selectively 
drive the expansion of a pathogenic IL-17-expresssing CD4+ T cells in EAE disease 
independent of IFN-γ and IL-4 (Langrish et al., 2005). Following the work, two 
independent groups characterized a novel TH subset, named IL-17-expressing T cells 
(TH17), whose differentiation from naïve T cells is distinct from TH1 and TH2 
(Harrington et al., 2005; Park et al., 2005). By now, intensive studies have revealed 
the differentiation programme and biological functions of TH17 cells (reviewed in 
Chapter 1.4).  
TH1, TH2 and TH17 are three major TH populations that protect host against infectious 
pathogens, but could also cause serious damage to the host if aberrant immune 
responses are triggered, such as autoimmunity and allergy. The quality and magnitude 
of adaptive immune responses are controlled by another CD4+ T cell population, 
called Treg. Treg cells can derive from thymus CD4+ T cells, called natural Treg (nTreg), 
but also can differentiate from peripheral naïve CD4+ T cells, called inducible Treg 
(iTreg). Thymus-derived nTreg cells with surface marker CD4+CD25+ specifically 
express Foxp3 (Forkhead box P3), a mater regulator of Treg development and function. 
Foxp3+ nTreg cells are maintained by IL-2 (Sakaguchi et al., 2008). Peripheral naïve 
CD4+ T cells can acquire Foxp3 expression and immune suppressive function upon 
TCR activation in the presence of TGF-β (Chen et al., 2003; Kretschmer et al., 2005). 
IL-2 and retinoic acid can promote iTreg differentiation from naïve T cells (Benson et 
al., 2007; Coombes et al., 2007; Elias et al., 2008; Fontenot et al., 2005; Mucida et al., 
2007; Sun et al., 2007). Interestingly, IL-2 and retinoic acid suppress TH17 
differentiation, although TGF-β potently promotes IL-17 expression (Elias et al., 2008; 
Laurence et al., 2007; Mucida et al., 2007). STAT5 activated by IL-2 directly binds to 
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Foxp3 promoter and induces its expression, thus STAT5 is critical for iTreg 
development (Yao et al., 2007). 
Recently, several other types of TH (TH9, TH22, TFH) cells have been described, but 
whether they are distinct lineages or just represent heterogeneity within each lineage 
discussed above is not certain. During T cell activation, TGF-β and IL-4 together 
induce high level of IL-9 production (Dardalhon et al., 2008; Veldhoen et al., 2008b). 
IL-9-expressing helper T (TH9) cells selectively express transcription factor PU.1 and 
these cells play an important role in allergic inflammation and autoimmunity (Chang 
et al., 2010; Noelle and Nowak, 2010; Perumal and Kaplan, 2011).  
IL-22-expressing helper T (TH22) cell differentiation has not been well studied, but it 
may be induced by IL-6 and augmented by IL-23 (Basu et al., 2012). IL-22 is critical 
in host defense against bacterial infractions at barrier sites. Accordingly, TH22 has 
been shown to protect host against enteropathogenic bacteria (Basu et al., 2012). In 
addition, TH22 may be involved inflammatory disorders (Eyerich et al., 2009; Xu et 
al., 2013).  
T follicular helper (TFH) cells are the specialized population that is critical for the 
formation of germinal centers. Within the germinal centers, TFH cells regulate B cells 
differentiation into plasma cells and memory B cells, which are the crucial players in 
the humoral immune response. TFH cells were initially described as a large proportion 
of CD4+ T cells expressing high level of CXCR5 in tonsils (Breitfeld et al., 2000; 
Kim et al., 2001; Schaerli et al., 2000). Recently, the identification of BCL6 (B cell 
leukemia/lymphoma 6) as a master regulator and IL-21 as a hallmark cytokine, has 
demonstrated TFH as a distinct CD4+ T cell lineage (Johnston et al., 2009; Linterman 
et al., 2010; Nurieva et al., 2008; Nurieva et al., 2009; Yu et al., 2009a; Zotos et al., 
2010). Exposure to IL-6 or IL-21 during CD4+ T cell activation promotes TFH 
differentiation (Dienz et al., 2009; Nurieva et al., 2008; Suto et al., 2008), but several 
other models for TFH differentiation are also proposed in disagreement with this 
model (Crotty, 2011).  Nevertheless, TFH differentiation is controversial, and the 
developmental relationship between TFH and other TH subsets remains elusive.   
The concept of CD4+ T cell lineage made sense: cytokine cues secreted by 
microbe-activated innate immune cells induce the differentiation of naïve CD4+ T 
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cells into particular effector cells, which produce certain set of cytokines for 
orchestrating immune responses and develop into memory T cells with high 
specificity. However, the emergence of new TH subsets and the plasticity of cytokine 
secretion by committed TH cells revolutionize our understanding on the properties of 
CD4+ T cells in immunoregulation (O'Shea and Paul, 2010). For instance, acquisition 
of IFN-γ secretion by TH17 cells, particularly simultaneous secretion of IFN-γ and 
IL-17, is commonly occurred (Lee et al., 2009; Wilson et al., 2007). TH1 cells under 
certain circumstances produce IL-13 (Hayashi et al., 2007). Thus, are these TH subsets 
considered as different lineages with certain plasticity? Or are they never committed 
and readily changing the properties according to environmental clues? More questions 
require further exploration.  
 
1.4 TH17 cell differentiation and effector functions 
Since TH17 was characterized as a new TH subset (reviewed in 1.3), TH17 induction 
and function has been intensively and widely studied. TGF-β in concert with 
inflammatory cytokines, IL-6 or IL-21, initiates the differentiation of naïve CD4+ T 
cells into TH17 cells (Bettelli et al., 2006; Korn et al., 2007; Nurieva et al., 2007), and 
this process is enhanced by tumor necrosis factor α (TNF-α) and IL-1 β (Veldhoen et 
al., 2006). IL-23 doesn’t act on naïve CD4+ T cells by initiating differentiation, but is 
believed to expand, stabilize or promote terminal differentiation of effector TH17 cells 
(Langrish et al., 2005; McGeachy et al., 2009; Stritesky et al., 2008).  
TGF-β alone induces Foxp3 expression and Treg generation through the canonical 
Smad2/3-Smad4 pathway. The presence of IL-6 inhibits the effect of TGF-β on Treg 
generation and induces naïve T cell differentiation into TH17. As a key molecule 
downstream IL-6 signaling, STAT3 mediates the most effect of IL-6 on the induction 
of IL-17, IL-17F, IL-21, IL-22 and IL-23R during TH17 differentiation (Yang et al., 
2007a; Zhou et al., 2007). In addition, STAT3 directly regulates the transcription of 
multiple genes encoding transcription factors that are crucial for TH17 differentiation, 
including Rorc, Rora, Ahr, Irf4 (Brustle et al., 2007; Ivanov et al., 2006; Veldhoen et 
al., 2008a; Yang et al., 2008b). The orphan nuclear receptor RORγt (encoded by Rorc 
gene) is selectively expressed in the presence of TGF-β and IL-6, and is considered as 
TH17 lineage-specifying transcription factor. Ectopic expression of RORγt alone in 
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naïve T cells is able to induce the development of TH17 cells, while the ablation of 
Rorc diminishes TH17 generation both in vitro and in vivo (Ivanov et al., 2006). TH17 
cells are constitutively present in the intestinal lamina propria and their development 
dependents on RORγt. However, Rorc deletion in mice does not completely abrogate 
TH17 cells, which is further explained by the compensatory effect of RORα (Yang et 
al., 2008b). RORα is also selectively induced by TGF-β and IL-6 in TH17 cells, but it 
seems to be a minor player compared with RORγt. The aryl hydrocarbon receptor 
(AhR) is selectively expressed in TH17 and it plays a crucial role in the cytokine 
production, in particular IL-22 (Veldhoen et al., 2009). AhR activation is stimulated 
by ligands, thus it might provide a link between TH17-meadiated autoimmune 
diseases and environmental toxins (Quintana et al., 2008; Veldhoen et al., 2009). 
Likewise, two independent groups reported environmental salt, through the induction 
of SGK1, can enhance the pathogenic properties of TH17 cells and drive the 
development of autoimmune diseases (Kleinewietfeld et al., 2013; Wu et al., 2013). 
The regulators discussed above are selectively induced or activated in TH17 cells 
compared with other subsets. Some regulators involved in CD4+ T cell activation and 
proliferation are also critical for TH17 differentiation. TCR activation by cognate 
antigen induces the activation of NF-κB, NFAT and AP-1 signaling pathways. NF-κB 
(nuclear factor of kappa light polypeptide gene enhancer in B cells) signaling is 
necessary for chromatin accessibility and cytokine expression in TH17 cells and for 
TH17-mediated autoimmunity (Brustle et al., 2012; Molinero et al., 2012). NFAT 
(nuclear factor of activated T cells) can directly bind to Il17 promoter and regulate its 
expression (Ghosh et al., 2010; Hermann-Kleiter et al., 2012). BATF (basic leucine 
zipper transcription factor, ATF-like), belonging to AP-1 protein family, is essential 
for RORγt induction and IL-17 production (Schraml et al., 2009). IRF4 (interferon 
response factor 4) appears to regulate RORγt expression and is indispensible for TH17 
differentiation as well as pathogenicity (Brustle et al., 2007).  In addition, IRF4 is a 
decisive factor during IL-21-drived TH17 development by regulating multiple 
transcription factors (Huber et al., 2008). The effect of IRF4 is further illustrated by 
its functional cooperation with STAT3 in modulating TH17 development (Kwon et al., 
2009). IRF4 is not specific to TH17 cells, because it also plays important roles in TH2 
and Treg cells (Lohoff et al., 2002; Rengarajan et al., 2002; Zheng et al., 2009).   
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TH17 cells potently produce the hallmark cytokine IL-17, which contributes to most 
TH17-mediated effects. IL-17 is the prototypic cytokines of IL-17 family, which 
consists of IL-17A to F (Kolls and Linden, 2004). In addition to IL-17, TH17 cell also 
produce large quantities of IL-17F (Langrish et al., 2005; Liang et al., 2006). Both 
IL-17 and IL-17F can recruit neutrophils to the inflamed tissues, and their expression 
is associated with several types of inflammatory diseases, such as asthma and 
rheumatoid arthritis (Kolls and Linden, 2004). More importantly, IL-17 is crucial in 
host defense against fungi and certain bacterial infection (Chung et al., 2003; Huang 
et al., 2004; Infante-Duarte et al., 2000; Khader et al., 2007). IL-21 and IL-22 are 
preferentially though not exclusively expressed by TH17. Autocrine IL-21 amplifies 
differentiating TH17 cells and is important in the development of colitis-associated 
colon cancer and uveitis (Nurieva et al., 2007; Stolfi et al., 2011; Wang et al., 2011). 
IL-22 is upregulated by IL-23 and mediates dermal inflammation, acanthosis and 
antimicrobial responses (Liang et al., 2006; Zheng et al., 2007).  
 
1.5 Experimental autoimmune encephalomyelitis and autoreactive T cell 
responses 
Experimental Autoimmune Encephalomyelitis (EAE) is the rodent model of human 
multiple sclerosis (MS), in which encephalitogenic T cells are believed to drive the 
disease onset. MS is an inflammatory demyelinating disease happening at central 
nervous system (CNS) in humans. Epidemiologically, MS is thought to happen in 
genetically predisposed individuals upon the triggering by environmental factors. In 
this process, autoreactive CD4+ T cells migrate to the CNS where they get reactivated 
by residential antigen presenting cells (APCs), resulting in the recruitment of myeloid 
cells and subsequent demyelination and axonal damage (Fig. 3).  
To initiate MS or EAE, myelin-specific CD4+ T cells are first activated in periphery 
before migrating to the CNS. In the past decades, TH1 cells were thought as the 
primary effector T cells in EAE. This view is supported by several lines of evidence. 
The expression level of TH1-related cytokines (IFN-γ and IL-12) in the CNS is 
correlated with clinical activity in MS (Gutcher and Becher, 2007). In EAE, IFN-γ 
secretion is detected in CNS-infiltrating T cells and more importantly adoptive 
transfer of TH1 cells is able to induce the disease (Baron et al., 1993; Segal and 
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Shevach, 1996). In the CNS, IFN-γ induces the production of chemokines and the 
expression of MHC II, both of which facilitate the entry of myeloid cells. 
 
 
Figure 3 Peripheral myelin-specific CD4+ T cell activation, migration and 
reactivation in the CNS. 
[Modified from (Goverman, 2009)] 
Peripheral CD4+ T cells are primed by myelin antigen presented by APCs. 
Myelin-specific CD4+ T cells enter into the brain through choroid plexus, where they 
are reactivated by residual APCs. Reactivated CD4+ T cells trigger the activation of 
microglial cells and blood vessels, resulting in the recruitment of more T cells and 
myeloid cells cross the blood-brain barrier. T cells invade the parenchyma and, 
together with other immune cells cause the demyelination. 
 
However, over the past decade, increasing observations conflict with this simple 
paradigm. Either IL-12p35 or IFN-γ deficient mice are still susceptible to EAE 
(Steinman, 2007). In addition, their receptors IFN-γR and IL-12Rβ2 are also 
dispensable for EAE induction (Willenborg et al., 1996; Zhang et al., 2003). In 
contrast, antibody neutralizing IL-12p40 subunit, or IL-12p40 deficiency protects 
mice from EAE (Gran et al., 2002; Leonard et al., 1995). IL-12 is a heterodimer 
cytokine composed of two subunits, IL-12p40 and IL-12p35. Based on the studies 
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described above, deletion either subunit leads to two distinct results. This paradox was 
firstly explained by the work from Daniel Cua’s group. In fact, IL-12p40 subunit is 
double used by both IL-12 and IL-23. IL-23 is also a heterodimer cytokine composed 
of IL-12p40 and the other unique subunit IL-23p19. Their work further demonstrated 
that IL-23-specific p19, but not IL-12-specific p35 is indispensible for EAE 
development (Cua et al., 2003). Meanwhile, this finding raises a question of how 
IL-23 executes its function in EAE.   
Recently, our understanding on the function of CD4+ T cells in EAE has greatly 
broadened since the discovery of TH17. Regarding the function of IL-23, Harrington 
et al. reported that IL-23 maintained and expanded differentiating TH17 cells as well 
as stabilized TH17 phenotype (Harrington et al., 2005). After the characterization as a 
novel TH cell subset, numerous studies support TH17 as the primary pathogenic 
effector cells in EAE. Increased IL-17 expression is detected in chronic MS lesions 
compared with control tissue from healthy individuals (Lock et al., 2002). Loss of 
RORγt or STAT3, master regulators of TH17 cells, attenuates the development of 
EAE disease (Ivanov et al., 2006; Liu et al., 2008). Moreover, adoptive transfer of 
TH17 cells seems to induce more severe disease compared with TH1 transfer (Langrish 
et al., 2005). Neutralizing antibody against IL-17 is reported to ameliorate EAE 
(Hofstetter et al., 2005b). These findings tend to strengthen the notion that TH17 cells 
are the ‘true’ effector cells in CNS autoimmune diseases. Surprisingly, unlike IL-23, 
either Il17-/- or Il-17f-/- mice are still susceptible to EAE (Haak et al., 2009). On the 
basis of these studies above, it is difficult to define the pathogenic roles of either TH1 
or TH17 in EAE. Currently, one relatively popular view is that both TH1 and TH17 
cells participate in EAE development, but TH17 cells are more important to drive the 
onset of this disease in the early stage whereas TH1 cells play a major role in the later 
stage. However, as described above, none of feature cytokines secreted by either TH1 
or TH17 cells is indispensible for EAE development. It is necessary to figure out how 
autoreactive T cells mediate EAE development. 
Sonderegger et al. pioneered the work to indicate that GM-CSF could be one of the 
cytokines secreted by autoreactive T cells that mediated the disease development in 
EAE (Sonderegger et al., 2008a). Furthermore, two groups reported back-to-back that 
the encephalitogenicity of TH17 as well as TH1cells was dependent the production of 
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GM-CSF induced by IL-23 and IL-1β (Codarri et al., 2011; El-Behi et al., 2011). 
Nicely, these three studies build a loop to explain the roles of TH17 and TH1 cells in 
EAE development: autoreactive T cells migrate to the CNS and secret GM-CSF, 
which mediates the recruitment of inflammatory macrophage to initiate the disease; 
GM-CSF also acts on dendrite cells by promoting the production of IL-23, which in 
turn drives the maturation of TH17 cells and the secretion of more GM-CSF. IL-23 
and IL-1β are thought to be the stimuli for GM-CSF production, but these two studies 
obtained opposite results with respect to the role of RORγt in GM-CSF expression. 
What are the transcription factors that directly activate Csf2 gene expression remain 
largely unknown. STAT proteins have been well established as the major transmitters 
of cytokine signaling. IL-23 is reported to activate STAT1, STAT3 and STAT5 in T 
cells (Parham et al., 2002). It is promising to explore the role of STATs in GM-CSF 
expression and EAE development.  
 
1.6 Inflammatory bowel disease and helper T cell responses 
The gastrointestinal (GI) tract harbors huge amount of microbial flora, including at 
least 395 different bacterial phylotypes, which constantly stimulate the mucosal 
immune system (Eckburg et al., 2005). However, there is no obvious inflammation in 
the GI tract of healthy person. The GI homeostasis is strictly maintained by several 
lines of mechanism, such as epithelium barrier and production of anti-microbial 
peptides, to prevent the occurrence of infectious disease or inflammation on the other 
hand (Hooper and Gordon, 2001). Inflammatory bowel disease (IBD) is chronic 
inflammatory disorders of the GI tract with unknown etiology. Generally, the 
pathogenesis of IBD is mediated by aberrant immune responses directed towards 
commensal bacteria or their products and also the functional loss of epithelial barrier 
(Xavier and Podolsky, 2007).  
Crohn’s disease (CD) and ulcerative colitis (UC) are two major IBD in humans. CD 
usually affects the intestines, but can occur anywhere of GI tract. UC affects the lining 
of colon and rectum, and consists of diffuse mucosal inflammation. CD is 
characterized by a marked mucosal infiltration of TH1 cells, secreting high level of 
IFN-γ (Parronchi et al., 1997). By contrast, UC is associated with aberrant TH2 
response, with the abundant production of IL-4 and IL-13 in especial (Heller et al., 
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2005; Inoue et al., 1999). Recently, the intensive studies on the newly characterized 
TH17 cells greatly advance our understanding on the pathogenesis of IBD.  
 
 
Figure 4 Dysregulation of immune homeostasis in inflamed intestine of CD. 
[Modified from (Abraham and Cho, 2009)] 
In normal intestine, microbe-triggered immune response was suppressed by Treg to 
reach a homeostasis. There is a balance between proinflammatory and 
anti-inflammatory cytokine production. During CD, the increased proportion of 
effector T cells and innate immune cells accompanied with high level of 
proinflammatory cytokines cause intestine inflammation.  
 
Several murine models of IBD resembling CD are used to study TH1 pathogenesis 
(Fig. 4). Trinitrobenzene sulfonic acid (TNBS)–induced colitis and T cell 
transfer–induced colitis show that the administration of IL-12p40 neutralizing 
antibody reverses the intestinal inflammation (Liu et al., 2001; Neurath et al., 1995). 
IL-12 is the key cytokine for driving TH1 generation. T-bet is the master transcription 
factor to drive the development of TH1 cells, thus both are essential for TH1 
pathogenesis in colitis (Neurath et al., 2002). IFN-γ, secreted by TH1 cells under the 
driving by IL-12 and T-bet, is the major mediator of TH1 pathogenesis in colitis 
(Powrie et al., 1994). Patients with CD exhibit enhanced IL-12 production in lamina 
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propria compared to healthy controls (Fuss et al., 2006; Matsuoka et al., 2004). 
Together, these findings provide the basis for the development of a humanized 
antibody against IL-12p40 for the treatment of CD patients. Clinical trials of 
anti-IL-12p40 show promising therapeutic efficacy (Mannon et al., 2004; Sandborn et 
al., 2008).  
Under normal condition, the immune homeostasis is established and maintained by a 
balance between effector T cells and Treg cells and a balance between 
proinflammatory cytokines and anti-inflammatory cytokines. During CD, immune 
homeostasis is disrupted and intestinal inflammation is accompanied with increased 
proportion of effector T cells and elevated expression of proinflammatory cytokines.  
UC is associated with elevated expression of TH2-related cytokines. The unaltered 
IFN-γ production rules out the contribution of TH1-driven inflammation. Several 
murine colitis models have been used to study the pathogenesis of TH2 in UC. In 
particular, oxazolone administration colitis model well exhibits the characteristics of 
UC of human (Strober et al., 2002). Oxazolone colitis exhibits increased IL-4 and 
TGF-β expression but not IFN-γ. Neutralizing antibody against IL-4 prevent the 
colitis, whereas anti-IL-12 exacerbate the disease. Lamina propria T cells from UC 
patients produce much higher level of IL-13 than that from CD patients (Fuss et al., 
2004).  
IL-23, together with IL-12 and IL-27 belong to the IL-12 family of heterodimeric 
cytokines (Hunter, 2005). IL-23 consists of a unique p19 subunit and a p40 subunit 
shared with IL-12, and signals through a distinct receptor (Oppmann et al., 2000; 
Parham et al., 2002). IL-23 is primarily produced by dendritic cells triggered by 
microbial ligands or through CD40 activation (Kastelein et al., 2007). The realization 
that IL-12p40 deletion and IL-12p40 neutralizing antibody could attenuate the effect 
of both IL-12 and IL-23, leads to the reevaluation of T cell response and cytokine 
effect in colitis.  
Many aspects of IBD that had previously been ascribed to TH1 response, especially 
the IL-12-IFN-γ axis, have more recently been attributed to the effect of IL-23. By 
using different experimental mouse models, several groups concurrently reported that 
IL-23, but not IL-12, is essential for the development of IBD (Hue et al., 2006; 
CHAPTER 1 
	   20 
Kullberg et al., 2006; Uhlig et al., 2006). Work from T cell transfer model show that 
IL-23 depletion is associated with decreased proinflammatory responses in the 
intestine but has little effect on systemic inflammatory response (Hue et al., 2006). In 
H. hepaticus-induced colitis model, IL-12p35-deficient mice develop intestinal 
inflammation similar to WT mice, but IL-12p40 deletion as well as IL-12p40 
neutralization prevents the mice from colitis. T cell transfer colitis model using Rag-/- 
mice deficient in IL-23p19 displays attenuated colitis, thus further elucidate the 
requirement of IL-23 but not IL-12 for intestinal inflammation (Kullberg et al., 2006). 
Just one year before these reports, TH17 had been characterized as a distinct 
population of TH cells (Harrington et al., 2005; Park et al., 2005) and IL-23 drives the 
generation of pathogenic TH17 cells in autoimmune inflammation (Langrish et al., 
2005). These results indicate TH17 could be the primary effector in IBD (Fig. 4). 
Indeed, increased expression of TH17-related cytokines is observed in IBD patients. 
Tissue biopsies show elevated IL-17, IL-17F and IL-22 expression in inflamed tissues 
compared with those of healthy controls (Andoh et al., 2005; Fujino et al., 2003; 
Seiderer et al., 2008). In addition, genome-wide screening study identifies Il23r as an 
IBD-associated gene (Duerr et al., 2006). With these respects, intensive studies have 
been performed to explore the pathogenesis of TH17 in mouse colitis models. In the 
TNBS-induced colitis, IL-17R deficient mice are protected from colonic inflammation 
(Zhang et al., 2006). In agreement with this view, IL-17 is reported to stimulate the 
production of proinflammatory cytokines by colonic epithelial cells (Hata et al., 2002). 
Unexpectedly, in T cell transfer colitis model, IL-23-dependent colitis seems not to 
require IL-17 production by T cells, but seems due to the IL-23-mediated suppression 
of Treg induction in the colon (Izcue et al., 2008). In another study, neutralization of 
IL-17 leads to exacerbated inflammation in dextran sulfate sodium (DSS) –induced 
colitis in mice (Ogawa et al., 2004). Therefore, the real role of IL-17 in colitis is still 
controversial. Unlike IL-17, IL-17F is more accepted to be a proinflammatory 
cytokine. The deficiency of IL-17F results in a reduced inflammation in DSS-induced 
colitis (Yang et al., 2008a).  
Another TH17-secreted cytokine, IL-21 suppresses TGF-β-dependent expression of 
Foxp3, whereas promotes the differentiation of TH17 cells and contributes to the 
pathogenesis of colitis (Fantini et al., 2007). Consistently, IL-21-deficient mice are 
unable to upregulate the expression of TH17-associated molecules during gut 
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inflammation and are protected from DSS-induced colitis (Fina et al., 2008). Thus, 
autocrine IL-21 drives TH17 differentiation and contributes to the development of 
IBD.  
Unlike other TH17-related cytokines, IL-22 plays a protective role in IBD. IL-22 
expression is also elevated in CD patients. In mouse colitis model, the increased IL-22 
enhances the secretion of LPS-binding protein and thus may contribute to the 
prevention of systemic inflammation provoked by LPS (Wolk et al., 2007). Mice 
deficient of IL-22 have greater inflammation in both T cell transfer colitis model and 
DSS-induced colitis model (Zenewicz et al., 2008). Microinjection-based 
gene-delivery of IL-22 by targeting inflamed intestine is capable to ameliorate the 
disease in a TH2-mediated colitis model (Sugimoto et al., 2008). IL-22 activates 
STAT3 and might maintain the integrity of epithelial barrier through the induction of 
mucus-associated molecules and restitution of goblet cells (Sugimoto et al., 2008). 
Thus, IL-22 could be a therapeutic target for clinical treatment of IBD.  
 
1.7 Objectives 
Cytokine milieus determine naïve CD4+ T cell lineage commitment into different 
effector cells, which play a crucial role in host defense against various pathogens by 
orchestrating adaptive immunity. STAT proteins transmit cytokine signals and thus 
are also crucial for regulating T cell lineage commitment. STAT5 transmits IL-2 
signal which suppresses IL-17 expression during TH17 differentiation. STAT5 is 
usually considered as a transcription activator, but how STAT5 suppresses IL-17 
expression has not been well known. In addition, how IL-2 dynamically regulates 
TH17 differentiation remains unclear.  
The aberrant effector T cell responses to self-antigen could result in autoimmune 
diseases and inflammatory disorders. TH1 and TH17 cells are thought to mediate 
inflammation in both peripheral tissues and central nervous systems. But none of the 
TH1 and TH17 hallmark cytokines is mandatory for EAE development. It is debated 
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The aims of this study were: 
1) To investigate the mechanism behind STAT5-mediated suppression of IL-17 
expression and the dynamic regulation of TH17 differentiation by IL-2; 
2) More importantly, to characterize the role of STAT5 in regulating pathogenic 
helper T cells in autoimmune neuroinflammation and intestinal inflammation.  
Our study should contribute to the current opinion in heterogeneity and plasticity of 
helper T cell, and provide new insights into the pathology of EAE and MS. 
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CHAPTER 2 MATERIALS AND METHODS 
 
Mice 
Stat5f/f mice were provided by L. Hennighausen (National Institute of Diabetes and 
Digestive and Kidney Diseases). In brief, Stat5a/b locus, consisting of two adjacent 
genes Stat5a and Stat5b, is flanked by two loxP sites, which can be exercised by 
recombinase enzyme (Cre). Stat3f/f mice were generated as described (Welte et al., 
2003), in which exons 18-20, encoding SH2 domain of STAT3 protein, are flanked by 
two loxP sites. Cd4-Cre transgenic mice were generated by microinjection of the 
construct consisting of mouse Cd4 promoter/enhancer/silencer and Cre recombinase, 
and were purchased from Taconic Farms. Rag2-/- mice, which contain a disruption of 
Rag2 gene and fail to generate mature T or B lymphocytes, were obtained from 
Jean-Pierre Abastado (Singapore Immunology Network). All mice are on a C57BL/6 
genetic background and housed under specific-pathogen-free conditions at National 
University of Singapore. All experiments were performed with mice at 6~8 weeks old 
and approved by the Institutional Animal Care and Use Committee of NUS.  
Mouse genotyping 
The genetically modified mice were genotyped by conventional PCR with genomic 
DNA from mouse tail. A ~2 mm tail tip was snapped and lysed with digestion buffer 
supplemented with Proteinase K (0.4 mg/ml) at 56 ºC overnight. Tail lysate was 
diluted 2X with deionized H2O and 1 µl tail lysate was used for one PCR reaction. 
PCR reaction was set up according to the manufacture’s instruction (Promega). PCR 
products were separated by Agarose-gel electrophoresis containing EtBr and 
visualized by gel imaging system (GeneGenius).  
T cell purification 
Spleens and lymph nodes were harvested from mice at 6-8 weeks old. Single cell 
suspensions were generated by meshing the tissues through a 70 µl cell strainer (BD 
Bioscience). Lymphocytes were enriched by gradient centrifuge with Ficoll (GE 
Healthcare). After that, CD4+ T cells were isolated by positive selection (L3T4 
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magnetic beads) and magnetic separation (Miltenyi Biotech). For the purification of 
naïve CD4+ T cells, CD4+ T cells were further stained with fluorochrome-conjugated 
antibodies to CD4, CD25, CD44, CD62L, and CD4+CD25-CD62LhiCD44- population 
was sorted with FACS Aria. Cell purity is >98%.  
In vitro T cell differentiation 
Naïve CD4+ T cells were stimulated with plate-bound anti-CD3 (3 µg/ml; BD 
Pharmingen) and anti-CD28 (1 µg/ml; BD Pharmingen) in presence of different 
combinations of neutralizing antibodies and cytokines for 3~4 days: for neutral 
condition, no extra neutralizing antibodies or cytokines; for TH 1 conditions IL-12 (10 
ng/ml), and anti-IL-4 (10 µg/ml, BD Pharmingen); for TH 17 condition, hTGF-β (3 
ng/ml), IL-6 (20 ng/ml), anti-IFN-γ (10 µg/ml, eBioscience), and anti-IL-4 (10 µg/ml); 
for alternative TH 17 condition, IL-6 (20 ng/ml), IL-23 (10 ng/ml), IL-1β (10 ng/ml), 
anti-IFN-γ (10 µg/ml), and anti-IL-4 (10 µg/ml); for GM-CSF-expressing TH cell 
condition, IL-7 (5 ng/ml) and anti-IFN-γ (10 µg/ml). All cytokines were obtained 
from R&D Systems. All cells were cultured in RPMI 1640 supplemented with 10% 
FBS, 100 units/ml penicillin, 0.1 mg/ml streptomycin, 1% Sodium pyruvate, 1% 
non-essential amino acid and 5µM beta-mercaptoethanol. After 3~4 days polarization, 
cells were used for analysis.  
Flow cytometry and intracellular cytokine staining  
For surface staining, cells were washed in FACS buffer (1X PBS supplemented with 2% 
FBS ad 0.1% sodium azide) and then blocked with anti-CD16/32 (Fc receptor) 
antibody. The fluorochrome-conjugated antibodies were used for staining. 
Antibodies for cell surface staining: 
CD3e AF448 (145-2C11, BD Pharmingen), CD4 PB (RM4-5, BD Pharmingen), CD4 
PAC-Cy7 (GK1.5, Biolegend), CD8 PerCP-Cy5.5 (53-6.7, eBioscience), CD25 PE 
(PC61, Biolegend), CD44 APC (IM7, BD Pharmingen), CD62L FITC (MEL-14, 
Biolegend), CD45RB FITC (16A, BD Pharmingen), CD11b PE (M1/70, eBioscience), 
CD69 PE (H1.2F3, Biolegend), CXCR3 PE (173, Biolegend). 
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Antibodies for intracellular staining:  
IL-17 PE (TC11-18H10.1, Biolegend), IL-17 FITC (TC11-18H10.1, Biolegend), 
IFN-γ APC (XMG1.2, BD Pharmingen), RORγt APC (AFKJS-9, eBioscience), 
GM-CSF FITC (MP1-22E9, eBioscience),  
For intracellular cytokine staining, cells were washed and restimulated with 50ng/ml 
phorbol 12-myristate 13-acetate (PMA) and 500 ng/ml ionomycin in the presence of 
Golgiplug (1:1000 dilution, BD Pharmingen) for 4-5 hr. Cells were first stained for 
extracellular markers with specific antibodies, followed by fixation and intracellular 
staining with a Cytofix/Cytoperm kit from BD Pharmingen. Cells were acquired on 
the LSR II (BD Biosciences) and analyzed with FlowJo software (Tree Star). 
Protein preparation and immunoblotting 
Protein extracts were prepared from whole cell lysates with RIPA lysis buffer (150 
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris-HCl 
pH8.0) supplemented with protease inhibitor (cocktail form Roche) and phosphatase 
inhibitor (Roche). In brief, cells were washed twice with cold 1X PBS and lysed with 
sufficient RIPA lysis buffer for 15 min on ice. The protein extracts were collected 
after spinning down the cell lysates at 15,000 g for 10 min. Protein extracts (10-15 mg) 
were separated by SDS-Gel electrophoresis and transferred to PVDF membranes. 
After blocking with 5% milk, membranes were incubated with primary antibody at 
appropriate dilution overnight at 4 ºC. Membranes were washed with PBST (0.1% 
Tween-20), followed by incubation with HRP-conjugated secondary antibody 
(Bio-Rad). After washing, proteins were visualized by incubation with 
chemiluminescence reagent and exposure to film. Membranes were incubated with 
stripping buffer (Bio-Rad) to remove previous antibodies if second target protein was 
examined on the same membrane. Primary antibodies used for immunoblotting: 
STAT3 (Santa Cruz, C-20), SAT5 (Santa Cruz, C-17), pY705-STAT3 (Cell Signaling, 
#9131), pY694-STAT5 (Cell Signaling, #9151) and β–Actin (Santa Cruz, C-4). 
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RNA extraction and Real-Time PCR 
For small amount of cells, total RNA was extracted from cells with RNeasy kit 
(Qiagen) according to the manufacturer’s instruction. For large amount of tissues, 
tissues were homogenized in Trizol (Invitrogen) and total RNA was extracted 
according to the user manual. Complementary DNA (cDNA) was synthesized with 
Superscript reverse transcriptase (Invitrogen). Gene expressions were measured by 
7500 real-time PCR system (Applied Biosystems) with SYBR qPCR kit (KAPA). 
Actinb, Gapdh or 18s rRNA was used as internal control. The primer sequences are 
listed as below. 
Table 2 Primer sequences for quantitative RT-PCR. 
Target 
genes 





















176 bp (Lai Kwan Lam 
et al., 2008) 
IL-1β CTCACAAGCAGAGCACAAGC 
GGCCGAGGACTAAGGAGTCT 
196 bp (Lai Kwan Lam 
et al., 2008) 
IL-6 ATGGATGCTACCAAACTGGAT 
TGAAGGACTCTGGCTTTGTCT 
139 bp Primer bank 
GM-CSF TTTACTTTTCCTGGGCATTG 
TAGCTGGCTGTCATGTTCAA 












227 bp  
RORγt TTTGGAACTGGCTTTCCATC 
AAGATCTGCAGCTTTTCCACA 








100 bp (Ouyang et al., 
2011) 
18S RNA TGGTGGAGCGATTTGTCTGG 
TCAATCTCGGGTGGCTGAAC 
150 bp (Shi et al., 
2008) 
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Gapdh TGACCTCAACTACATGGTCTACA 
CTTCCCATTCTCGGCCTTG 
85 bp Primer bank 
β-Actin GGCTGTATTCCCCTCCATCG 
CCAGTTGGTAACAATGCCATGT 
154 bp Primer bank 
Chromatin Immunoprecipitation assay 
CD4+ T cells isolated from Stat5f/f or Cd4-Cre; Stat5f/f mice were activated with 
plate-bound anti-CD3 and anti-CD28 for 3 days. Cells were stimulated with IL-7 (20 
ng/ml) for 45 min. Crosslink was performed by addition of formaldehyde at final 
concentration of 1% for 10 min followed by quenching with Glycine. Cell lysates 
were fragmented by sonication and precleared with protein G Dynabeads, and 
subsequently precipitated with anti-STAT5 antibody (Santa Cruz, C-17) or normal 
rabbit IgG (Santa Cruz) overnight at 4oC. After washing and elution, crosslink 
reversal was done by incubating at 65oC for 8 hr. The eluted DNA was purified and 
analyzed by RT-PCR with primers specific to Csf2 promoter as described previously.  
Table 3 Primer sequences for ChIP-PCR. 




Csf2 Site 1 AAAAGGAGAGGCTAGCCAGA 
TAAGCCCTTCCAAGAACTGG 
(Chen et al., 2005) 
Csf2 Site 2 AAGGTCCTGAGGAGGATGTG 
GAGGTTCAGGGCTTCTTTGA 
(Chen et al., 2005) 
Luciferase reporter assay 
The Irf8 promoter fragment (-351 to 54 bp) was cloned into pGL4.17 luciferase 
reporter vector. The STAT5 binding sites in the Irf8 promoter fragment were mutated 
by site-directly mutagenesis according to the instruction manual (Stratagene). In a 
typical study, 0.5 µg pGL4.17-Irf8 (-351/54) construct was cotranscfected with 0.035 
µg pRL-TK (Renilla) into 293T cell with Lipofectamine 2000 kit according to the 
instruction manual (Invitrogen). In some cases, pLEGFP-c1 or pLEGFP-STAT5a 
(1*6) was transfect along with pGL4.17-Irf8 (-351/54) and pRL-TK. After 2 days 
transfection, cells were lysed and the dual-luciferase reporter system (Promega) was 
used to measure firefly and Renilla luciferase activity. Firefly luciferase activity was 
normalized to Renilla luciferase activity.  
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Retroviral transduction 
The retroviral constructs pMX-STAT5b-EGFP (obtained from Cao Xinmin, Institute 
of Molecular and Cell Biology, Singapore) and pLEGFP-STAT5b (1*6) (obtained 
from Toshio Kitamura, University of Tokyo, Japan) were used to transfect 
Phoenix-Eco cells. In brief, Phoenix-Eco cells were seeded without antibiotics one 
day before transfection. Transfection was done when the culture became 70-80% 
confluent with Lipofectamine 2000 (Invitrogen) according to the instruction manual. 
We changed to fresh medium 12 h after transfection and continued the culture till 48 h. 
The supernatant containing retroviral particles was collected and passed through a low 
protein-binding filter (0.45 µm). For the transduction of CD4+ T cells, cells were first 
activated with 3 µg/ml anti-CD3 and 1 µg/ml anti-CD28 for 24 hr. These activated 
cells were then transduced with retroviral supernatant by centrifugation at 2,000g for 
1.5 h at 30 °C in the presence of 8 µg/ml polybrene. After removing the supernatant, 
cells were washed with fresh medium and cultured with anti-CD3 and anti-CD28 for 
2-3 days before analysis. 
EAE induction 
EAE induction procedures were modified from previous report (Zhang et al., 2009). 
For active EAE induction, mice were immunized in two sites on the hind flanks with 
300 µg MOG35-55 in 100 µl CFA containing 5 mg/ml heat-killed M. tuberculosis strain 
H37Ra (Difco) at day 0 and day 7. Pertussis toxin (List Bio Lab) was administrated 
intraperitoneally at the dosage of 500 ng per mouse at day 1 and day 8. Clinical 
symptoms were scored as follows: 0, no clinical sign; 1, loss of tail tone; 2, wobbly 
gait; 3, hind limb paralysis; 4, hind and fore limb paralysis; 5, death. For EAE 
induction in Rag2-/- mice, Rag2-/- mice were adoptively transferred with 8 million 
CD4+ T cells derived from Stat5f/f or Cd4-Cre; Stat5f/f mice, followed by 
MOG35-55/CFA immunization as described above. IL-7Rα neutralizing antibody and 
isotype control (BD Pharmingen) were administrated intraperitoneally at 200 µg per 
mouse every other day. STAT5 inhibitor was administrated intraperitoneally at 200 
mg/kg per mouse every other day starting from post immunization. For the analysis of 
CNS-infiltrating cells, both spinal cord and brain from perfused mice were collected 
and minced, and mononuclear cells were isolated by gradient centrifuge with percoll 
(GE Healthcare).  
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T cell transfer-induced colitis 
CD4+ T cells were isolated from spleens and lymph nodes of WT, Cd4-Cre; Stat3f/f 
and Cd4-Cre; Stat5f/f mice by positive selection and magnetic separation (Miltenyi 
Biotech). Naïve CD4+ T (CD4+CD25-CD45RBhi) cells were sorted with BD FACS 
Aria (purify>98%). Rag2-/- mice were reconstituted with 0.4 million naïve CD4+ T 
cells via intraperitoneal injection. Intestine inflammation was monitored up to 8 
weeks. Body weight was measured every week. For the analysis of cellular 
compositions, cell suspensions were prepared from spleen, mesenteric lymph nodes 
(MLNs), and colon lamina propria (LP) by methods modified from previous report 
(Uhlig et al., 2006). In brief, colons were harvested from sacrificed mice and flushed 
with cold PBS to remove the feces. Then the colons were cut into pieces by 0.5-1 cm 
and digested with Solution I at 37 ºC for 15 min to remove intraepithelial 
lymphocytes. Colon pieces were further digested with Solution II to release LP 
lymphocytes (LPLs). LPLs were enriched by Percoll gradient centrifuge. Enriched 
LPLs were collect from the interface and analyzed by flow cytometry.  
Solution I: HBSS + 5%FBS + 2mM EDTA + 0.15 mg/ml (1mM) DTT + 10 mM 
HEPES 
Solution II: 5%FBS+ 1.5 mg/ml Collagenase VIII + 0.1 mg/ml DNase I in PBS 
Histological analysis 
For paraffin-embedded tissues, spinal cords or colons were fixed in 4% PFA 
overnight at 4 °C. Tissues were dehydrated with serial concentration of ethanol (70% 
- 80% - 95% - 100% - 100%), cleared with xylene and infiltrated with paraffin wax. 
After processing, tissues were embedded in paraffin wax. Sectioning was performed 
using a microtome. Sections (5 µm) were de-waxed in xylene and re-hydrated serial 
concentration of ethanol (100% - 95% - 80% - 70% - H2O). Then sections were 
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Immunofluorescence staining 
Immunofluorescence staining was performed with cryosections. In brief, fresh tissues 
were embedded in OCT (Tissue-Tek) and snap frozen on dry ice. Sections (10 µm) 
were fixed in ice-cold acetone. Before staining, sections were washed with cold PBS 
and permeabilized in PBS containing 0.25% Triton X-100. After washing, sections 
were incubated with 1% BSA in PBST to block nonspecific binding. Then sections 
were stained with primary anti-CD4 (Biolegend) and anti-CD11b (eBioscience) 
overnight at 4 °C, followed by incubation with fluorescence-conjugated secondary 
antibodies (Invitrogen) for 1 h at room temperature. Incubate sections with DAPI for 
2 min to visualize nucleus.  
ELISA 
GM-CSF and IL-2 levels were assayed by Ready-SET-Go ELISA kit (eBioscience), 
and IL-17 level was measured by DuoSet ELISA kit (R&D Systems) according to the 
manufactures’ instructions. 
RNA-seq  
RNA samples for RNA-seq were extracted from cells with RNeasy kit (Qiagen) 
according to the manufacturer’s instruction. Briefly, mRNA was enriched by 
Poly(A)-RNA selection and fragmented. It then underwent first- and second-strand 
synthesis to produce productions ready for cDNA library construction. The 
sequencing of cDNA was performed with pair-end read and at 76 bp in length on 
Illumina platform. The RNA-seq reads were aligned and quantified for transcriptome 
analysis. A Volcano plot is a scatter plot that is used to analyze high-throughput data 
sets to give an overview of gene expression. The log fold change was plotted on the 
x-axis and the negative log10 p-value was plotted on the y-axis. K-means clustering 
was used to identify clusters of gens with similar expression profiles.  
Statistics 
Statistical significance was determined by Student’s t test using GraphPad Prism 6.01. 
The p value<0.05 was considered significant. The p values of clinical scores were 
determined by one-way multiple-range analysis of variance (ANOVA) for multiple 
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comparisons. Unless otherwise specified, data were presented as mean and the 
standard error of the mean (mean ± SEM).  
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TH17 is well known as a major helper T cell subset, which plays a crucial role in host 
defense against fungi and certain bacterial infection. The differentiation of TH17 from 
naïve CD4+ T cell is driven by the cooperative effect of TGF-β and IL-6, and this 
process can be further enhanced by TNF-α and IL-1 β (Veldhoen et al., 2006). IL-23 
expands and stabilizes TH17 cells and endows TH17 with pathogenicity (Langrish et 
al., 2005; McGeachy et al., 2009; Stritesky et al., 2008). Recently, it is reported that 
TH17 can be generated in the absence of TGF-β (Ghoreschi et al., 2010). 
TH17 differentiation and effector cytokine expression is modulated by the extensive 
interaction of different transcription factors. TGF-β in concert with IL-6 induces the 
expression of RORγt (encoded by Rorc gene), the master regulator of TH17 lineage.  
STAT3 transmits IL-6 signaling and thus is crucial for TH17 differentiation. It is 
known that STAT3 directly binds to the promoter of Rorc gene (Durant et al., 2010), 
whereas TGF-β signaling pathway is less understood in TH17 differentiation. TGF-β 
promotes Treg generation by upregulating Foxp3, but suppresses TH1 and TH2 
generation by downregulating T-bet and GATA3 (Gorelik et al., 2002; Gorelik et al., 
2000; Park et al., 2007). However, during TH17 differentiation, IL-6-induced STAT3 
activation can suppress TGF-β-induced Foxp3 expression so that prevent Treg 
generation. Furthermore, RORγt also suppresses Foxp3 expression to restrain the 
antagonistic role of Foxp3 in TH17 differentiation (Burgler et al., 2010). Besides these 
two key regulators, Runx1 is reported to positively regulate Il17 transcription by 
inducing RORγt expression and by physically interacting with RORγt (Zhang et al., 
2008). BATF, belonging to AP-1 transcription factor families, is also important for 
RORγt induction (Schraml et al., 2009). However, the induction/activation of Runx1 
and BAFT during TH17 differentiation remains unclear.  
Interferon-regulatory factors (IRF), including IRF1 to IRF10, have been well known 
for playing a crucial role in regulating virus-IFN axis. But many IRFs are now 
impacted in regulating helper T cell differentiation. For instances, IRF1 and IRF2 
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promote TH1 response, whereas IRF4 is required for TH2 differentiation (Lohoff and 
Mak, 2005). IRF4 has also been characterized critical for TH17 differentiation. Loss 
of IRF4 attenuates TH17 generation and prevents mice against autoimmunity (Brustle 
et al., 2007). Further study shows that IRF4 is responsible for IL-21-mediated TH17 
amplification and stabilization (Huber et al., 2008). The genome-wide ChIP-Seq 
reveals a functional cooperation of IRF4 and STAT3 in response to IL-21 signal 
(Kwon et al., 2009). The activity of IRF4 is regulated by IRF4-binding protein (IBP), 
which sequesters IRF4 and prevents IRF4-inudced expression of IL-17 and IL-21 
(Chen et al., 2008). A ROCK2 kinase can activate IRF4 by phosphorylation, which 
further induces the production of IL-17 and IL-21 during TH17 differentiation (Biswas 
et al., 2010). IRF8 can act as an activator or suppressor depending on the co-activator. 
IRF8 expression in T cell is induced by TCR engagement, but its regulation and 
function in T cell response has not been well understood. Recently, in one study, IRF8 
is defined as a suppressor of TH17 differentiation (Ouyang et al., 2011). Mice with T 
cell-specific deletion of IRF8 exhibit increased TH17 generation and they are more 
susceptible to autoimmunity. 
TH17 differentiation is negatively regulated by several other cytokines, including IL-4, 
IFN-γ, IL-27 and IL-2. IL-2 is previously reported to promote Treg differentiation by 
activating STAT5 and by inducing Foxp3 expression (Fontenot et al., 2005). 
Interestingly, IL-2 suppresses IL-17 expression independent of Foxp3 induction but 
exclusively dependent on STAT5 activation (Laurence et al., 2007). Furthermore, 
Yang and colleagues proposed that STAT5 competed with STAT3 for binding to 
Il17-Il17f locus, which resulted in gene silencing by introducing suppressive histone 
modification (Yang et al., 2011). However, unlike IL-17, IL-17F expression appears 
not suppressed by IL-2 in the presence of IL-6, even though histone modifications at 
both promoters are almost simultaneously regulated. This raises a question whether 
there is other mechanism behind the suppressive effect of IL-2 on TH17 differentiation. 
Moreover, it is also interestingly to study how other TH17-related cytokines such as 
IL-21 and IL-22 are regulated by IL-2. 
In this chapter, we first reproduced that IL2-STAT5 suppressed TH17 differentiation. 
Furthermore, we analyzed the dynamic process of TH17 differentiation and the 
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regulatory effect of IL-2 using RNA-Seq. Our preliminary data indicated that IRF8 
could be a target of STAT5 and may contribute to the suppressive effect of IL-2.   
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3.2 Results 
3.2.1 The opposite roles of IL-6-STAT3 and IL-2-STAT5 signaling in TH17 
differentiation  
STAT3 is a crucial transcription factor for TH17 differentiation by transmitting 
inflammatory cytokine signals. We first reproduced that loss of STAT3 (CD4-Cre, 
Stat3f/f or Stat3 CFF) abrogated IL-17+ cell generation in vitro (Fig. 5a). But the 
number of RORγt+ cells was only modestly influenced by STAT3 deletion (Fig. 5a). 
We further confirmed this result with RT-PCR which showed a dramatically reduced 
expression of IL-17 and IL-17F mRNA in Stat3-deficient TH17 cells (Fig. 5b). 
Consistently, RORγt mRNA was only slightly decreased (Fig. 5b).  
IL-2-STAT5 signaling is important for Foxp3 induction and Treg generation. 
Conversely, during TH17 differentiation, IL-2 suppressed IL-17+ cell generation in a 
dosage-dependent manner (Fig. 6a). The blocking of endogenous IL-2 using 
neutralizing antibody enhanced IL-17+ cell generation (Fig. 6b). As reported, IL-2 
activated STAT5 by inducing tyrosine phosphorylation in CD4+ T cells detected by 
pY694-STAT5a/b specific antibody (Fig. 6c). Expectedly, the abrogation of STAT5 
attenuated IL-2-induced suppression of TH17 differentiation (Fig. 6d). Interestingly, 
IL-7, also signaling through γc receptor and activating STAT5, did not suppress 
IL-17+ cell generation (Fig. 6d). We would further explore the function of IL-7 in the 
following chapters.  
Similarly to a previous report (Yang et al., 2011), we found that unlike IL-17, IL-7F 
mRNA expression was not suppressed by IL-2 in TH17 cells (Fig. 6e). Given the 
histone modification at the promoter regions of Il17 and Il17f appeared to be 
simultaneously regulated in response to extracellular cytokine signals (Yang et al., 
2011), there should be other mechanisms behind the differential gene expression. We 
also observed that IL-21 mRNA expression was even increased by IL-2, while IL-22 
mRNA expression was inhibited by IL-2 in a STAT5-independent manner (Fig. 6e). 
Next we studied how IL-2 regulated TH17 differentiation.  
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Figure 5 Loss of STAT3 abrogates TH17 differentiation. 
(a) Sorted naïve CD4+ T cells from Stat3 FF (Stat3f/f) and Stat3 CFF (CD4-Cre; 
Stat3f/f) mice were primed with anti-CD3 and anti-CD28 in the presence of TGF-β and 
IL-6 for 3-4 days. The expression of IL-17 and RORγt was measured by intracellular 
staining and flow cytometry. 
(b) The expression of IL-17, IL-17F and RORγt was measured by RT-PCR. The 
RT-PCR data were normalized to β-Actin, and expression in Stat3 FF medium was 
set to 1.  
Data are representative of two independent experiments. *p<0.05, ns, not significant. 
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Figure 6 IL-2 suppresses TH17 differentiation in a STAT5-dependent manner. 
(a,b) Intracellular staining of IL-17 and IFN-γ in TH17-polarized cells in the presence 
of various concentrations of IL-2 (a) or IL-2 neutralizing antibody (b).  
(c) CD4+ T cells were stimulated with IL-2 or IL-6 for the detection of STAT5 
activation by pY694-STAT5a/b specific antibody and immunoblotting.  
(d) Flow cytometric analysis of IL-17 and IFN-γ expression in Stat5 FF (Stat5f/f) and 
Stat5 CFF (CD4-Cre; Stat5f/f) naïve CD4+ T cells differentiated in vitro with 
cytokines as indicated.  
(e) RT-PCR analysis of IL-17, IL-17F, IL-21 and IL-22 mRNA expression in 
polarized cell as in d. The RT-PCR data were normalized to β-Actin, and expression 
under Stat5 FF medium was set to 1. 
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3.2.2 RNA-Seq analysis of TH17 differentiation and the regulation by IL-2 
To better understand the process of TH17 differentiation, we performed the RNA-Seq 
analysis of whole transcript in naïve CD4+ T cells differentiated under 
TH17-polarizing condition for 0, 1 2 and 3 days. The activated CD4+ T cells (day 1, 2, 
3) displayed a remarked change of gene expression profile compared with naïve CD4+ 
T cells. However, global gene expression was not changed a lot between day 1, day 2 
and day 3, indicating a critical regulation of genome-wide gene expression within 24 
h of T cell activation. A short-term (30 min) stimulation of naïve CD4+ T cells by 
IL-2 only had modest effect on whole transcript (Fig. 7a). In addition, the comparison 
of transcripts with or without exposure to IL-2 at day 1, day 2 or day 3 showed that 
only a small group of genes was significantly changed by IL-2 (Fig. 7a). These data 
suggest the effect of IL-2 on TH17 differentiation is limited or specific. We clustered 
the differential expressed genes in the time-course of TH17 differentiation into four 
groups (Fig. 7b). Group 1 showed a constant increase of expression during the whole 
course of cell differentiation or at least in the first two days. Interestingly, this group 
characterized cytokines and cytokine receptors including IL-17, IL-17F, IL21, CCR6, 
IL-23R and IL-1R1 etc, which were previously identified as TH17 feature molecules 
(Fig. 7b, top left and Fig. 7c, top). Goup 4 displayed a quick induction of gene 
expression within 24 h of TH17 polarization. Gene expression in this group reached a 
peak at day 1, but didn’t increase further in the subsequent two days (Fig. 7b, bottom 
right and Fig. 7c, bottom). Transcription factors important for TH17 differentiation, 
including RORγt, RORα, IRF4, Ahr and Maf etc, fell into this group. Our results 
suggest a model that during TH17 differentiation, TCR activation together with 
cytokine milieus quickly induces the expression of a specific goup of transcription 
factors, which may form a regulatory network and induce the abundant production of 
effector cytokines by differentiated cells.  
The exposure to exogenous IL-2 suppressed the induction of TH17-related cytokines 
and cytokine receptors at day 2 and day 3 but not at day 1, suggesting a indirect effect 
of IL-2 (data not shown). We hypothesized that IL-2 induced the expression of 
suppressive trancription factors within one day, which subsequently restrained 
cytokine expression at later stage of TH17 differentation. IRF family proteins are now 
being studied in the regulation of T cell differentiation. We observed a dramatic 
increase of IRF4 expression within one day, which has been demonstrated to paly a 
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crucial role in TH17 differentation (Brustle et al., 2007; Huber et al., 2008; Kwon et 
al., 2009). Thus, we decided to examine the expression of IRF family proteins. In the 
RNA-Seq data, we found that IRF8 expression was also quickly induced during TH17 
differentation, but it gradually went down at later stage (Fig. 7d). The exposure to 
IL-2 sustained IRF8 expression at relatively higher level (Fig. 7e), which drew our 
attention due to the dual funtions of IRF8 in gene transcription.  
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Figure 7 Dynamic transcript analysis of TH17 differentiation by RNA-Seq. 
(a) Volcano plot (log fold change against -log10 p-value) for Pairwise analysis of the 
differential expressed genes by naïve CD4+ T cells differentiated under 
TH17-polarizing condition for 0, 1d, 2d and 3d with or without exposure to exogenous 
IL-2. Day 1_c, Day 2_c and Day 3_c represent without exposure to IL-2, whereas 
Day 1, Day 2 and Day 4 represent exposure to IL-2. A 30-min exposure to IL-2 of 
naïve CD4+ T cells was also considered as day 0. Each point represents the mean 
expression level plotted against the fold change for a given sequence. Black points are 
not statistically significant, and red points are significant at P < 0.01. 
(b) K-means clustering differential expressed genes by TH17-polarizing cells without 
exposure to exogenous IL-2 at different time points. 
(c) Representative gene expression of cluster 1 (top) and cluster 4 (bottom) in b. 
(d) IRF family gene expression by TH17-polarizing cells at different time points. 
(e) IRF8 expression by TH17-polarizing cells at day 0, 1, 2, 3 with or without 
exposure to exogenous IL-2.   
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3.2.3 IRF8 may contribute to the suppressive effect of IL-2-STAT5 signaling 
In our RNA-Seq analysis, we found a quick induction of IRF8 mRNA expression 
upon naïve T cell activation within one day. But IRF8 mRNA expression gradually 
went down at later stage of TH17 differentiation. Interestingly, the addition of 
exogenous IL-2 sustained the expression of IRF8 mRNA at a relatively higher level. 
IRF8 can act as a transcription suppressor. We next verified whether IRF8 expression 
was regulated by IL-2 and studied what was the function of IRF8 in TH17 
differentiation.  
We first examined the protein expression of IRF8 in TH17 cells and found that TH17 
expressed similar level of IRF8 as that in cells differentiated under neutral condition 
(Fig. 8a). Our finding was not consistent with a previous report that TGF-β 
upregualted IRF8 expression (Ju et al., 2007). As expected, IL-2 remarkably increased 
IRF8 protein expression (Fig. 8a). Furthermore, the exposure to IL-2 during TH17 
differentiation induced higher level of STAT5 activation detected by antibody against 
tyrosine-phosphorylated STAT5 (Fig. 8b). The result suggests that STAT5 activation 
may mediate IL-2-induced IRF8 expression. To further confirm this, we differentiated 
STAT5-defecient naïve CD4+ T cells with a combination of various cytokines. We 
observed that loss of STAT5 attenuated most induction of IRF8 by IL-2 (Fig. 8c). 
Notably, in the absence of IL-6, TGF-β together with IL-2 induced the highest IRF8 
expression (Fig. 8b,c), suggesting that IL-6 may suppress IRF8 expression in the 
process of TH17 differentiation. We also transduced CD4+ T cells with retrovirus 
expressing constitutive active STAT5 (EGFP-STAT5b-ca) and detected a marked 
increase of IRF8 protein compared with cells transduced with GFP empty vector or 
normal STAT5b retroviral construct (Fig. 8d). Together, our results demonstrate that 
IL-2 upregulates IRF8 expression in STAT5-depedent manner during T cell 
activation.  
To understand the mechanism behind IL-2/STAT5-mediated IRF8 induction, we 
stimulated TH17 cells with IL-2 and measured IRF8 mRNA expression at various time 
after stimulation. We found that IL-2 induced IRF8 mRNA expression within 30 min 
(Fig. 9a). Given STAT5 acts as a signal transducer and transcription factor, we 
hypothesized that STAT5 activated by IL-2 may directly transcribe IRF8 expression. 
To confirm this hypothesis, we first analyzed the proximal promoter (<500bp) of Irf8 
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gene and found several putative transcription factor (TF) binding sites predicted by 
PROMO software (Fig. 9b). One putative STAT5 binding site was clearly identified 
at approximate 186 bp upstream of the transcription starting site (TSS). A more 
detailed analysis showed it consisted of one conserved STAT5 consensus binding site 
(S1) and one adjacent less conserved site (S2) (Fig. 9c). Thus, we designed a pair of 
primers flanking these two sites for the ChIP assay to detect STAT5 binding. As 
expected, we detected that STAT5 bound to this region in CD4+ T cells and this 
binding was enforced by IL-2 stimulation (Fig. 9d).  
To validate that STAT5 binding sites were functionally involved in Irf8 transcription, 
we inserted a 400 bp promoter fragment into pGL4.17 reporter vector. Transfection of 
pGL4.17 reporter containing Irf8 promoter fragment (pGL4.17-IRF8 (-351/54)) into 
293T cells resulted in a strong luciferase signal compared with empty vector, 
indicating the promoter fragment is functionally active (Fig. 9e). The cotransfection 
of construct expressing STAT5a (1*6) (also called STAT5A-ca) and pGL4.17-IRF8 
(-351/54) enhanced the luciferase signal by approximate 2-fold (Fig. 9e). Furthermore, 
we mutated either or both of these two putative STAT5 binding sites (Fig. 9f). The 
cotransfection of these mutants and construct expressing STAT5a (1*6) showed that 
S1 or S1/2 mutation significantly reduced the luciferase signal, but S2 mutation had 
no obvious effect (Fig. 9g). Taken together, our data support that STAT5 activated by 
IL-2 binds to the promoter of Irf8 and transcribes its expression in activated T cells.    
While we were carrying on this study, IRF8 was characterized as negative regulator in 
TH17 differentiation by one group (Ouyang et al., 2011). In their study, loss of IRF8 
resulted in more efficient TH17 generation and thus IRF8 was believed to direct a 
silencing programme in TH17 differentiation. Considering the suppressive effect of 
IRF8 in TH17 differentiation, we proposed that IRF8 at least partially contribute to the 
suppressive effect of IL-2 on TH17 differentiation. 
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Figure 8 IRF8 expression in TH17 cells is upregulated by IL-2-STAT5 signaling. 
(a) Immunoblotting of IRF8 expression in naïve CD4+ T cells polarized with TGF-β 
and IL-6, or in the presence of IL-2.  
(b) Naïve CD4+ T cells were differentiated with cytokines as indicated for 3 days. The 
STAT5 activation and IRF8 expression were detected by immunoblotting. 
(c) Quantitative RT-PCR analysis of IRF8 mRNA expression in Stat5 FF and Stat5 
CFF naïve CD4+ T cells differentiated with cytokines as indicated. 
(d) CD4+ T cells were activated with anti-CD3 and anti-CD28 for 24 h and then 
infected with retrovirus expressing GFP, STAT5b or constitutive EGFP-STAT5b-ca. 
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Figure 9 STAT5 activated by IL-2 directly induces IRF8 expression. 
(a) IRF8 mRNA expression by TH17 cells at various time after stimulation with IL-2. 
The RT-PCR data were normalized to β-Actin, and expression without IL-2 
stimulation was set to 1. 
(b) The analysis of significant putative TF binding sites within Irf8 promoter using 
PROMO software. 
(c) The STAT5 consensus binding sites within Irf8 promoter of several mammals 
were aligned.  
(d) The ChIP assay was performed with IL-2-stimulated CD4+ T cells using normal 
IgG or STAT5-specific antibody. The binding of antibodies to Irf8 promoter region 
was detected by RT-PCR  
(e) Luciferase activity of 293T cells transfected with empty reporter construct, or 
reporter construct containing Irf8 (-351/54) promoter fragment, or together with 
construct expressing constitutive active STAT5 (STAT5a (1*6)). 
(f) Reporter constructs containing Irf8 (-351/54) promoter fragment with one or two 
mutations at STAT5 consensus binding sites.  
(g) Luciferase activity of 293T cells transfected with construct expressing constitutive 
active STAT5 and reporter constructs as shown in f.    
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3.3 Discussion 
In this Chapter, we first reproduced that STAT3 is crucial for TH17 differentiation 
(Fig. 5). In the contrast, STAT5 is a negative regulator for TH17 differentiation by 
transmitting IL-2 signal (Fig. 6). IL-2 has been considered necessary for T cell 
survival and proliferation for a long time. However, lessons from knockout mice have 
demonstrated that the dominant biological function of IL-2 signal is to retrain T cell 
activation and prevent autoimmunity. This immune suppressive effect of IL-2 largely 
attributes its role in promoting Treg generation as reviewed by Malek (2008). 
Furthermore, our study together with previous reports shows that IL-2 prevents 
autoimmunity possibly also through inhibiting TH17 generation, a crucial effector in 
tissue inflammation and autoimmune disorders. We presented data showing that IL-2 
suppressed IL-17 expression but not IL-17F (Fig. 6e). But the decreased IL-17 
expression appeared to be independent of RORγt, whose expression was only 
modestly influenced by IL-2 (Fig. 7c). Previously, it has been proposed that IL-2 
suppressed IL-17 expression by changing histone modification (Yang et al., 2011). 
However, we noticed that although Il17f locus shared the similar histone modification, 
its expression was not inhibited by IL-2. Furthermore, how IL-2 dynamically 
regulates TH17 differentiation has not been well known. 
To gain a more comprehensive understanding of TH17 differentiation and the 
regulatory role of IL-2, we analyzed the dynamic transcript profile during TH17 
differentiation with or without exposure to IL-2. Our data support that upon TCR 
activation under TH17-polarizing condition, a specific group of transcription factors 
are quickly upregulated, which may form a regulatory network and induce the 
abundant expression of effect cytokines. The effect of IL-2 on TH17 differentiation 
may be limited or specific, because only a small group of genes were significantly 
influenced by IL-2 exposure. 
IRF8 expression was quickly induced after T cell activation and reached a peak within 
one day (Fig. 7e). But the role of IRF8 in this process remains unknown. IL-17 
expression began to be significantly upregulated only after day 1 (Fig. 7c), while 
IRF8 expression gradually dropped down. In this regard, it appears that IRF8 need to 
be downregulated to support the optimal induction of IL-17. Consistent with this 
speculation, IRF8 was recently characterized as a negative regulator in TH17 
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differentiation (Ouyang et al., 2011). The exposure to IL-2 during TH17 
differentiation sustained IRF8 expression at relatively higher level (Fig. 8). We 
presented data showing STAT5 activated by IL-2 directly bound to the promoter of 
Irf8 and transcribed its expression (Fig. 9). Taken together, we conclude that IRF8 
could at least partially contribute to the suppressive effect of IL-2 on TH17 
differentiation (Fig. 10). Our data also showed that TGF-β together with IL-2 potently 
induced IRF8 expression, which was suppressed by IL-6 (Fig. 8b). It would be 
interesting to study what is the role of IRF8 in Treg cells and how IL-6 modulates the 
balance between TH17 and Treg.  
 
 
Figure 10 A diagrammatic summary of IL-2/STAT5-mediated suppressive effect 
on IL-17 expression in TH17 cells. 
IL-2-induced STAT5 activation can directly bind Il17 gene promoter. Additionally, 
STAT5 induces IRF8 expression, which can suppress Il17 expression. 
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Chapter 4 STAT5 is required for the encephalitogenicity of autoreactive 
helper T cells 
 
4.1 Introduction 
Multiple sclerosis (MS) is a human chronic neuroinflammatory disease characterized 
by demyelination and axonal degeneration. MS affects 1 in 1000 people, often young 
women, and causes variable manifestations including motor dysfunction, visual 
impairment, spasticity and fatigue. Although the pathogenesis of MS is far from being 
well understood, MS is widely considered as an autoimmune disease, in which the 
immune system aberrantly reacts against myelin self-antigen. T cells appear early on 
the neurologic lesions and are likely to be one of the major effectors in disease 
progression. Epidemiologically, susceptibility to MS is resulted from a combination 
of genetic factors and environmental risk factors. With the advance in high throughput 
sequencing technology, recent genome-wide association studies in MS have identified 
novel risk loci with multiple variants that may play a key role in disease susceptibility. 
In these studies, genes related to immune responses, particularly helper T cell 
differentiation, are significantly overrepresented among the mapping close to the 
identified loci (Sawcer et al., 2011). Importantly, it should be recognized that those 
disease-associated genetic variants in MS may not be casual factors but may be just 
markers. Thus, the difficulty lies in determining whether a genetic variant is a true 
disease-causing factor. In this aspect, functional studies play the indispensible roles.  
In the functional study of genetic factors in MS pathogenesis, EAE mice model is 
commonly used (Baxter, 2007). In general, to initiate EAE, myelin antigen-specific T 
cells are activated in periphery, and gain access to the CNS where they are reactivated 
by APCs that present self-antigen. T cell activation induces the production for soluble 
mediators that attract the entry of myeloid cells, and together they cause inflammation 
and demyelination. 
Evidence from genetically modified mice strongly supported the notion that TH17 
instead of TH1 cells could be the major drivers in EAE (Steinman, 2007). This 
indicates that factors regulating TH17 generation could be functionally related to EAE 
pathogenesis. IL-23, which is important for TH17 expansion and stabilization, is 
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crucial for EAE development (Cua et al., 2003; Harrington et al., 2005). The 
disruption of RORγt, the master regulator of TH17 cells, has been reported to prevent 
mice against EAE disease (Ivanov et al., 2006). IL-6-STAT3 signaling is necessary 
for TH17 differentiation, and thus the disruption of either gene causes the resistance to 
EAE (Liu et al., 2008; Samoilova et al., 1998).  
In contrast to IL-6-STAT3 signaling, IL-2-STAT5 signaling suppresses TH17 
differentiation in vitro (see Chapter 3). Based on the antagonistic role of STAT5 in 
TH17 differentiation, it would be expected that CD4+ T cell-specific deletion of 
STAT5 will cause enhanced TH17 generation in mice and increased susceptibility to 
TH17-mediated autoimmune diseases, including EAE. But what is the real role of 
STAT5 in TH17-mediated autoimmune neuroinflammation in vivo has not been 
reported.  
In this Chapter, we characterized for the first time the role of STAT5 in the 
encephalitogenicity of autoreactive helper T cells. Our findings demonstrate that 
STAT5 actually is required for effector CD4+ T cell-mediated EAE development. 
Furthermore, loss of STAT5 in CD4+ T cells causes an intrinsic defect in their 
encephalitogenic potential.  
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4.2 Results 
4.2.1 Stat3 conditional deletion protects mice from EAE  
STAT3 is a crucial transcription factor in TH17 differentiation. Thus, it is anticipated 
that disruption of STAT3 will abrogate TH17 differentiation and prevent mice against 
TH17-mediated autoimmune diseases. To reproduce the finding that STAT3 is 
required for CD4+ T cell pathogenicity, we induced EAE in Cd4-Cre; Stat3f/f (Stat3 
CFF or Stat3-/-) mice, where Stat3 is specifically deleted in T cell compartment, and 
in littermate controls (Lee et al., 2001). We immunized Stat3 FF and Stat3 CFF mice 
with MOG35-55/CFA at day 0 and day 7, followed by pertussis toxin (PTX) injection. 
Development of paralysis was assessed by daily assignment of clinical scores. Stat3 
FF mice developed classic symptoms of EAE ranging from loss of tail tone, hind limb 
weakness to ascending paralysis. As expected, Stat3 CFF mice were resistant to EAE 
(Fig. 11a). 
We further analyzed properties of CNS-infiltrating cells and found the presence CD4+ 
T cells was significantly reduced in Stat3 CFF mice compared with control (Fig. 11b). 
This indicates that Stat3-deficient CD4+ T cells lack encephalitogenicity and are 
unable to induce neuroinflammation. To assess the presence of TH1 and TH17 cells, 
we stimulated the CNS-infiltrating cells with PMA/Ion in the presence of Golgiplug 
(protein transport inhibitor) and analyzed the cytokine production by CD4+ T cells. 
Indeed, loss of STAT3 diminished IL-17 production in CD4+ T cells, but IFN-γ 
production was not affected (Fig. 11c). Numerous studies have established the critical 
role of TH17 in EAE development (Ivanov et al., 2006; Langrish et al., 2005; Reboldi 
et al., 2009). Our findings further confirm that STAT3 is necessary for pathogenic 
TH17 generation and EAE development.   
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Figure 11 Stat3-conditional knockout mice are resistant to EAE. 
(a) Clinical EAE scores of Stat3 FF and Stat3 CFF mice (n=5 per group) immunized 
twice with MOG35-55/CFA. 
(b) The CNS-infiltrating mononuclear cells were isolated from EAE mice (n=4 per 
group). The proportion of CD4+ T cells was analyzed by flow cytometry. The right 
panel showed the statistical analysis.  
(c) IL-17 and IFN-γ expression by CNS-infiltrating CD4+ T cells (n=4 per group) was 
measured by intracellular cytokine staining. The right panel showed the statistical 
analysis. 
*p<0.05, **p<0.005; ns, not significant. 
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4.2.2 Stat5 conditional knockout mice are resistant to EAE 
STAT5 negatively regulates TH17 differentiation by restraining IL-17 production (Fig. 
6). However, the function of STAT5 in TH17-mediated pathogenesis is not well 
understood. We speculated that CD4+ T cell-specific deletion of STAT5 would 
exacerbate autoimmune neuroinflammation. To explore this question, we induced 
EAE in Cd4-Cre; Stat5f/f (Stat5 CFF or Stat5-/-) mice. We immunized Stat5 FF and 
Stat5 CFF mice with MOG35-55/CFA at day 0 and day 7. Development of paralysis 
was assessed by daily assignment of clinical scores. Surprisingly, we found 
diminished occurrence and severity of clinical disease in Stat5 CFF mice (Fig. 12a), a 
result that was opposite to expectations based on an antagonistic role for STAT5 in 
TH17 generation.  
To further confirm clinical signs of EAE, we evaluated CNS inflammation 
histologically. Stat5 deletion resulted in a remarkable reduction of immune cell 
infiltration in the spinal cord examined by H&E staining (Fig. 12b). Furthermore, 
both CD4+ and CD11b+ cell infiltration were reduced in Stat5 CFF mice when 
detected by specific antibodies and immunostaining (Fig. 12c). To further analyze the 
cellular composition of CNS-infiltrating immune cells, we isolated cells from both 
brain and spinal cord of Stat5 FF and Stat5 CFF mice at day 14 (peak) after the 
second immunization. Consistent with the section staining data, infiltration of both 
CD4+ T and CD11b+ cells were significantly reduced in Stat5 CFF mice examined by 
flow cytometry (Fig. 12d,e). Taken together, these data demonstrate that Stat5 
conditional knockout mice are resistant to EAE with reduced neuroinflammation in 
the CNS.  
Next we wondered whether the disruption of STAT5 activation by chemical inhibitor 
would phenocopy Stat5 mutant symptom in EAE induction. The phosphorylation on 
the key tyrosine residue in SH2 domain is crucial for STAT5 activation and function. 
A commercial STAT5 inhibitor (CAS 285986-31-4, Calbiochem) has been reported to 
selectively disrupt tyrosine phosphorylation and DNA binding of STAT5 (Muller et 
al., 2008). Thus, we administrated this commercial STAT5 inhibitor to wild-type mice 
intraperitoneally every other day after MOG35-55/CFA immunization. Development of 
paralysis was assessed by daily assignment of clinical scores. We found that STAT5 
inhibition ameliorated EAE severity, although the inhibitor was not as efficient as 
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Stat5 deletion. This data indicates that targeting STAT5 by chemical inhibitor might 
be useful in therapeutic intervention in MS.  
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Figure 12 Stat5-conditional knockout mice are resistant to EAE. 
(a) Clinical EAE scores of Stat5 FF and Stat5 CFF mice immunized twice with 
MOG35-55/CFA peptide. Data represent more than three independent experiments.  
(b) Histology of spinal cord sections obtained from EAE mice at day 9 after 2nd 
immunization. Images shown are representative of two independent experiments with 
three mice per group. Scale bars, 200 µm (top), 50 µm (bottom).  
(c) CD4+ and CD11b+ cells in spinal cord sections were stained by 
immunofluorescence. Images shown are representative of two independent 
experiments with three mice per group. Scale bars, 200 µm.  
(d,e) CNS mononuclear cells were analyzed by flow cytometry at day 14 (peak) after 
2nd immunization. Plots in (d) were gated on CD45hi cells. Right panels are cell 
proportions or cell numbers pooled from two experiments (n=9).  
(f) Stat5 FF mice were injected with STAT5 inhibitor intraperitoneally every other 
day after first MOG35-55/CFA immunization. Clinical scores were shown versus days. 
The p values of clinical scores were determined by one-way multiple-range analysis 
of variance (ANOVA) multiple comparisons. 
*p<0.05, **p<0.005, ***p<0.0005.  
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4.2.3 Stat5 mutant mice have no defect in peripheral immune response to 
MOG35-55/CFA immunization  
Unexpectedly, we found Stat5 conditional mutant mice were resistant to EAE 
development (Fig. 12). Next, we wanted to address the cellular and molecular 
mechanism behind this phenomenon. 
To test whether the resistance of Stat5 CFF mice to EAE induction was caused by 
peripheral lymphopenia, we analyzed the cellular composition of spleens from Stat5 
CFF mice. In agreement with published findings (Yao et al., 2006), we observed a 
profound reduction of CD8+ T cells in the spleens of Stat5 CFF mice compared with 
Stat5 FF mice, but CD4+ T cells were comparable between two groups at day 7 of 
EAE induction (Fig. 13a). At day 21, although the peripheral CD4+ T cell percentage 
was lower in Stat5 CFF mice, the absolute number was not altered by Stat5 
deficiency (Fig. 13b). These data suggest that Stat5-/- CD4+ T cells can proliferate 
normally in response to antigen stimulation in vivo.  
T cell activation induces the secretion of autocrine IL-2, which is generally thought to 
promote T cell proliferation. We therefore examined the serum IL-2 level in Stat5 
CFF and control mice during EAE induction. Interestingly, we detected higher level 
of serum IL-2 in Stat5 CFF mice compared with control (Fig. 13c). Moreover, in 
recall antigen response, Stat5-deficient CD4+ T produced comparable level of IL-2 
(after normalization to the proportion of CD4+ T cell among splenocytes) when 
splenocytes were challenged with MOG35-55 (Fig. 13d). Together, these data show that 
Stat5 CFF mice have no defect in immune response to MOG35-55/CFA immunization 
and Stat5-deficient CD4+ T cells have no defect in activation and proliferation.   
We hypothesized that the resistance of Stat5 CFF mice to EAE induction was caused 
by an intrinsic defect of Stat5-/- CD4+ T cells in the encephalitogenicity. To test this 
hypothesis, we adoptively transfer CD4+ T cells derived from Stat5 FF and Stat5 CFF 
mice into Rag2-/- recipient mice. The reconstituted mice were immunized with 
MOG35-55/CFA and monitored for the clinical signs. We found that unlike the mice 
that received wild-type CD4+ T cells, mice that received Stat5-deficient CD4+ T cells 
were unable to develop EAE disease (Fig. 13e). Intracellular staining of STAT5 
confirmed its abrogation in CD4+ T cells obtained from Rag2-/- mice that received 
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Stat5-deficient CD4+ T cells (Fig. 13f). Expectedly, comparable numbers of CD4+ T 
cells were retrieved from spleens of Rag2-/- recipients (Fig. 12g). 
In summary, our data support that Stat5 deficiency causes an intrinsic defect of CD4+ 
T cell pathogenicity in EAE induction. Next, we want to study how STAT5 regulates 
the encephalitogenicity of autoreactive CD4+ T cells.  
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Figure 13 Disruption of STAT5 does not cause any defect in CD4+ T cell 
activation upon MOG35-55/CFA immunization. 
(a,b) Spleens were obtained from MOG35-55/CFA-immunized Stat5 FF and Stat5 CFF 
mice at day 7 (a) and day 21 (b). The proportions of CD4+ and CD8+ T cells were 
analyzed by flow cytometry. The absolute number of CD4+ T cells was calculated 
(right panels). Data are representative of two independent experiments (a) or pooled 
from two independent experiments (b).  
(c) Serum IL-2 of MOG35-55/CFA-immunized Stat5 FF and Stat5 CFF (n=9) mice at 
day 21 was measured by ELISA. Data are pooled from two independent experiments. 
(d) Splenocytes were isolated from EAE mice and challenged with MOG35-55 for 48 h 
for the measurement of IL-2 secretion by ELISA. 
(e) Rag2-/- mice (n=5 per group) were reconstituted with CD4+ T cells derived from 
Stat5 FF or Stat5 CFF mice, followed by twice MOG35-55/CFA immunization. 
Clinical scores were shown versus days. Data are representative of two independent 
experiments.  
(f) Spleens were obtained from Rag2-/- recipient mice as in e. STAT5 expression in 
CD4+ T cells was measured by intracellular staining with antibody against STAT5. 
(g) Spleens were obtained from Rag2-/- recipient mice as in e. The proportions of 
CD4+ and CD11b+ cells were analyzed by flow cytometry (left). The absolute number 
of CD4+ T cells was calculated (right).  
*p<0.05, **p<0.005, ***p<0.0005. 
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4.2.4 Stat5-deficient CD4+ T cells can migrate to the CNS but fail to sustain 
inflammation 
Next, we investigated whether the reduced neuroinflammation was caused by any 
defect in the migration of Stat5-deficient CD4+ T cells to the CNS. Since the 
chemokine receptor CCR6 has been identified to be essential for encephalitogenic 
TH17 entry into the CNS through the choroid plexus (Reboldi et al., 2009), we 
therefore examined CCR6 expression in both wild-type and Stat5-deficient CD4+ T 
cells. We found increased CD4+CCR6+ cells in spleens of Stat5 CFF mice compared 
with Stat5 FF controls (Fig. 14a). We also examined CXCR3 (for TH1 migration) and 
CD69 (T cell activation marker) expression by these CD4+ T cells and found 
increased expression of both molecules in CD4+ T cells in the absence of STAT5 (Fig. 
14a). These results indicate that Stat5-deficient CD4+ T cells are likely able to migrate 
to the CNS.  
To support this view, we harvest the whole CNS (brain and spinal cord) of EAE mice 
for infiltrate analysis after perfusion with 1X PBS. Expectedly, we observed 
comparable numbers of CD4+ T cells present in the CNS of Stat5 FF and Stat5 CFF 
mice at day 7 and day 9 (before onset) of EAE induction (Fig. 14b-d). However, 
dramatically fewer CD4+ T cells were found in the CNS of Stat5 CFF mice compared 
with control mice at day 21 (Fig. 14b-d). These data suggest that Stat5-deficient CD4+ 
T cells can migrate to the CNS but fail to induce neuroinflammation. The majority of 
Stat5 CFF mice had markedly reduced inflammatory cells in the CNS including CD4+ 
T cells at peak of disease as shown in Fig. 14b-d, but we observed that a certain 
proportion of Stat5 CFF mice contain comparable CD4+ T cells in the CNS compared 
with control mice (Fig. 14e, right panel). However, those mice still showed no or less 
disease severity (Fig. 14e, left panel).  Taken together, these results demonstrate that 
Stat5-deficient CD4+ T cells are activated and likely able to migrate to the CNS 
during EAE induction. 
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Figure 14 Stat5-deficient CD4+ T cells are able to migrate to the CNS. 
(a) Flow cytometric analysis of CCR6, CXCR3 and CD69 expression by CD4+ T cells 
among splenocytes isolated from EAE mice at day 21. The percentage of CCR6+, 
CXCR3+ or CD69+ cells among CD4+ T cells was indicated. Data are representative 
of two independent experiments with three to five mice per group.  
(b-d) CNS-infiltrating CD4+ T cells were analyzed at day 7, day 9 and day 21 during 
EAE development. The average percentage of CD4+ T cells in the CNS was shown in 
c. Absolute cell numbers were calculated in d. Data are representative of two 
independent experiments with three mice per group. 
(e) Clinical scores (left) and CNS-infiltrating CD4+ T cells (right) were analyzed at 
day 21 during EAE development. Data are pooled from three experiments.  
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4.2.5 Stat5 deletion causes impaired Treg development 
Treg cells play a critical role in maintaining immune tolerance to self-antigens and in 
suppressing excessive immune responses to non-self-antigens (Sakaguchi et al., 2008). 
Foxp3 is the master regulator of Treg development and function. CD25 (IL-2Rα) is a 
Treg–associated cell-surface molecule. It has been shown that enhanced Treg cell 
generation and activity can suppress EAE development (Bassil et al., 2011; Chen et 
al., 2006). Therefore, we assessed Treg cell development in the absence of STAT5 
during EAE induction. Nevertheless, we detected decreased CD4+CD25+ Treg 
population and reduced Foxp3 expression in Stat5-deficient CD4+ T cells (Fig. 15a,b), 
indicating the resistance to EAE is unlikely due to altered Treg cells. To further 
explore the role of STAT5 in Treg development, we purified naïve CD4+ T cells and 
differentiated them into iTreg cells with TGF-β and IL-2. We found that loss of STAT5 
downregulated Foxp3 expression (Fig. 15c). These results show that STAT5 is 
important for Treg cell development and the resistance of Stat5 CFF mice to EAE 
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Figure 15 STAT5 is important for Treg cell development. 
(a) Spleens were obtained from MOG35-55/CFA-immunized Stat5 FF and Stat5 CFF 
mice at day 21 (n=5). The proportions of CD25+ among CD4+ T cells were analyzed 
by flow cytometry.  
(b) Foxp3 expression by splenic CD4+ T cells of Stat5 FF and Stat5 CFF EAE mice 
was analyzed by flow cytometry. 
(c) Naïve CD4+ T cells were polarized in the presence of TGF-β and IL-2 for 3 days 
in vitro. The expression of Foxp3 was measured by RT-PCR. The RT-PCR data were 
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4.2.6 Enhanced TH17 and TH1 generation in Stat5 conditional mutant mice 
Given that we did not detect any defect in T cell activation, proliferation, migration 
and any aberrant immune suppression in the absence of STAT5, we hypothesized that 
STAT5 deficiency dampened the generation of encephalitogenic T cells. TH17 and 
TH1 have been considered as the major encephalitogenic effectors in autoimmune 
neuroinflammation. We therefore determined whether pathogenic TH17 and TH1 
generation was dampened by Stat5 deletion.  
In chapter 3, we have shown that STAT5 is a negative regulator of TH17 
differentiation. STAT5 activation by IL-2 potently suppressed IL-17 expression (Fig. 
6). Here we did the TH1 differentiation in vitro. Upon TCR activation, IL-12 induced 
naïve T cells differentiation into IFN-γ-producing (TH1) cells. Nevertheless, the 
addition of exogenous IL-2 did not have an obvious influence on TH1 differentiation 
(Fig. 16a). We observed that IL-7, another cytokine also signaling through the γc 
receptor, promoted IL-12-drived TH1 differentiation to some extent (Fig. 16a). 
Meanwhile, we did the in vitro differentiation with Stat5 knockout cells and found 
that TH1 differentiation was slightly reduced compared with control (Fig. 16a). 
Therefore, unlike in TH17, STAT5 appeared to be required for optimal TH1 
differentiation in vitro. These data show that STAT5 plays different roles in TH17 and 
TH1 differentiation in vitro.  
We next examine TH17 and TH1 cell generation in the context of EAE induction. We 
analyzed IFN-γ-producing and IL-17-producing CD4+ T cells in the spleens from 
Stat5 FF and Stat5 CFF EAE mice. Consistent with the in vitro data, significantly 
increased percentage of TH17 cells was found in spleens from Stat5 CFF mice than 
those from Stat5 FF mice (Fig. 16b). But in contrast to in vitro TH1 differentiation, we 
also observed relatively a higher percentage of TH1 cells in spleens from Stat5 CFF 
mice (Fig. 16b). We also measured the expression of other TH17 feature cytokines by 
CD4+ T cells in the absence of SAT5 but did not find any impairment (Fig. 16c). 
Given the similar numbers of splenic CD4+ T cells of Stat5 FF mice and Stat5 CFF 
mice (Fig. 13a,b), our data argue that TH17 and TH1 cell generation is enhanced rather 
than dampened by Stat5 conditional deletion in EAE disease. 
Encephalitogenic TH17 and TH1 cells are thought to migrate to the CNS and initiate 
neuroinflammation. We wondered whether CNS-infiltrating Stat5-deficient CD4+ T 
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cells were capable of maintaining the production of IL-17 and IFN-γ. To address this 
question, spinal cords were harvested for the analysis of cytokine expression during 
EAE induction. We found that both IL-17 and IFN-γ mRNA expression was induced 
in the spinal cord at day 7 of EAE induction when similar number of CD4+ T cells 
were present in the CNS of wild-type and knockout mice (Fig. 14d), whereas a 
slightly higher level of IL-17 was detected in Stat5 CFF mice compared with control 
(Fig. 16d, left). These data suggest that Stat5-deficient CD4+ T cells are capable of 
producing IL-17 and IFN-γ after migration to the CNS. At day 14, we detected lower 
level of IL-17 mRNA in in the spinal cord of Stat5 CFF mice than that of control 
mice (Fig. 16d, right). Given Stat5-deficient CD4+ T cells failed to sustain 
neuroinflammation (Fig. 14b,c), we reasoned that the lower level of IL-17 expression 
at later stage of EAE induction was due to the less absolute number of CD4+ T cells in 
the spinal cord of Stat5 CFF mice (Fig. 14d). To further validate our finding, we 
isolated the mononuclear cells from the CNS of EAE mice and analyzed the IL-17 
and IFN-γ expression by intracellular staining and flow cytometry. As expected, there 
were no significant differences in proportions of IL-17+ and IFN-γ+ populations 
among CNS-infiltrating CD4+ T cells between Stat5 CFF and control mice (Fig. 16e).  
In summary, CD4+ T cell-specific deletion of Stat5 results in enhanced generation of 
TH17 and TH1 cells in response to MOG35-55/CFA immunization. The Stat5-deficient 
CD4+ T cells are capable of producing IL-17 and IFN-γ in the CNS but not efficient to 
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Figure 16 Stat5-deficient CD4+ T cells are capable of producing IL-17 and IFN-γ. 
(a) Naïve CD4+ T cells were obtained from Stat5 FF and Stat5 CFF mice and primed 
under TH1-polarizing condition in the presence of IL-2 or IL-7. IL-17 and IFN-γ 
production was measured by intracellular cytokine staining. 
(b) IL-17 and IFN-γ expression by splenic CD4+ T cells of EAE mice (n=5 per group) 
was determined by intracellular staining and flow cytometry at day 14 after 2nd 
immunization. 
(c) Splenic CD4+ T cells were isolated from EAE mice (n=3 per group) at day 14 after 
2nd immunization and stimulated with anti-CD3 and anti-CD28 for the analysis of 
cytokine expression by RT-PCR. The RT-PCR data were normalized to β-Actin. 
(d) Spinal cords were obtained from Stat5 FF and Stat5 CFF mice (n=3 per group) at 
day 7 (left) or day 14 (right) after MOG35-55/CFA immunization. The mRNA 
expression of IL-17 and IFN-γ in the spinal cords was analyzed by RT-PCR. The 
RT-PCR data were normalized to 18S rRNA, and expression of naïve mice was set to 
1. 
(e) IL-17 and IFN-γ expression by CNS-infiltrating CD4+ T cells (n=5 per group) was 
determined by intracellular staining and flow cytometry at peak of disease. 
Data are representative of at least two independent experiments. *p<0.05. 
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4.3 Discussion 
STAT5 is a key molecule of cytokine signaling through γc-containing receptors, 
including IL-2, IL-7 and several other cytokines (Leonard and O'Shea, 1998). Our 
studies and previous reports have demonstrated that STAT5 is a negative regulator of 
TH17 differentiation program (Laurence et al., 2007; Yang et al., 2011), while 
mediates Foxp3 expression and Treg generation (Yao et al., 2007). Moreover, it is well 
documented that TH17 and Treg subsets have reciprocal roles in control of 
autoimmunity and inflammation (McGeachy and Cua, 2008). However, in the current 
study we reported a surprising finding that STAT5 is indispensable for T 
cell-mediated neuroinflammation in an EAE model (summarized in Fig. 17). 
Conditional Stat5 deletion in T cells is reported to cause peripheral lymphopenia (Yao 
et al., 2006). Thus, it would be taken for granted that the resistance of Stat5 CFF mice 
to EAE is owing to impaired CD4+ T cell generation. Nevertheless, the absolute 
number of splenic CD4+ T cells of Stat5 CFF mice was comparable to their littermate 
controls during EAE development. IL-2 functions through at least three major 
signaling cascades, JAK3-STAT5, MAKP and PI3K-Akt (Cacalano and Johnston, 
1999). It is possible that the other two signaling cascades are responsible for cell 
survival and proliferation in the absence of STAT5. Moreover, CD4+ T cells may 
switch to other signals instead of IL-2 for survival and proliferation. In this aspect, 
IL-6 has been reported to prevent apoptosis and promote proliferation of CD4+ T cells 
through STAT3 when IL-2 signaling is blocked (Takeda et al., 1998). 
Chemokine-chemokine receptor interaction serves a central function in orchestrating 
the trafficking of immune cells (Bromley et al., 2008). So far, there are over 50 
chemokines and 20 chemokine receptors have been identified. Several members of 
CCRs and CXCRs are important for T cell trafficking to the inflamed tissues 
(Bromley et al., 2008). The increased expression of CCR6 and CXCR3 indicates that 
the migration of TH17 and TH1 cell was not impaired by Stat5 deletion (Fig. 14a). We 
also screened the expression of most chemokine receptors in CD4+ T cells but did not 
find any obvious defect in the absence of STAT5 (data not shown). The observation 
that comparable numbers of CD4+ T cells were present in the CNS of Stat5 FF and 
Stat5 CFF EAE mice at early stage further confirmed that Stat5-deficient CD4+ T 
cells are able to migrate to the CNS (Fig. 14b-d). Then the question is why T 
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cell-specific loss of STAT5 actually leads to the suppression of neuroinflammation in 
the EAE model. 
TH17 and to less extent TH1 are considered as the major encephalitogenic effectors in 
autoimmune neuroinflammation (Goverman, 2009). Although we have shown that 
STAT5 negatively regulates TH17 generation in vitro (Fig. 6), the exact role of 
STAT5 in TH17 and TH1 generation under pathogenic condition has not been explored 
yet. In this regard, we analyzed IL-17 and IFN-γ production by Stat5-deficient CD4+ 
T cells during EAE induction. However, we did not detect any defect in IL-17 and 
IFN-γ production in both spleens and the CNS in the absence of STAT5 (Fig. 16b,e). 
In fact, TH17 and TH1 generation was enhanced in the spleens of Stat5 CFF mice. 
Increased TH17 cells can be explained by the loss of IL-2-induced suppression when 
STAT5 was absent. But for TH1 cells, we got opposite results from in vitro and in 
vivo experiments. We showed that STAT5 may be required for optimal IFN-γ 
expression in vitro, consistent with a previous report. In that report, Min Shi and 
colleagues proposed JAK3-STAT5 signaling induced chromatin remodeling and 
increased accessibility in Ifng promoter (Shi et al., 2008). But they only did the in 
vitro differentiation with similar procedures as ours. We think that TH1 differentiation 
in vitro simply driven by exogenous IL-12 may not represent the complexity of T cell 
immune response in vivo, particularly under pathogenic condition. Nevertheless, 
enhanced TH1 generation could be partially explained by impaired immune 
suppression by Treg cells in the absence of STAT5.  
Autoreactive T cells migrate to the CNS and initiate neuroinflammation. In our 
experiment, we indeed found Stat5-deficient TH17 and TH1 cells can invade the CNS 
and were capable of producing IL-17 and IFN-γ. But why they cannot sustain the 
neuroinflammation and induce paralysis in mice? We will address this question in the 
next Chapter.  
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Figure 17 A diagrammatic summary of attenuated neuroinflammation and 
resistance to EAE in Cd4-Cre, Stat5f/f mice. 
The peripheral immune responses to MOG35-55/CFA immunization are competent in 
Cd4-Cre, Stat5f/f mice. Antigen-specific TH1 and TH17 cells are generated and able to 
migrate to the CNS. However, Stat5-deficient TH1 and TH17 cells are unable to induce 
neuroinflammation despite of the secretion of IFN-γ and IL-17.   
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Chapter 5 IL-7-STAT5 signaling regulates a novel GM-CSF-expressing 




A distinct CD4+ T cell lineage can be characterized by three criteria: specific cytokine 
milieu for differentiation, lineage-specifying transcription factors and unique 
expression profile of effector cytokines. In the past few years, the relevant 
information has been well recognized and established TH17 as a distinct helper T cell 
lineage (reviewed in Chapter 1.4).  
Previously TH1 was thought to be the primary effector T cell in the pathology of MS 
and EAE. The view is supported by the observation that the expression of IFN-γ and 
IL-12 in the CNS is associated with MS and that TH1 cells were present in the CNS of 
EAE mice (Gutcher and Becher, 2007). More direct evidence comes from the ability 
of TH1 cells to induce neuroinflammation by adoptive transfer to naïve mice (Segal 
and Shevach, 1996). However, the discovery of TH17 eventually revolutionizes our 
understanding on the pathology of MS and EAE. Numerous findings have emerged to 
support the view that TH17 rather than TH1 is the primary encephalitogenic population 
(reviewed in Chapter 1.5). The most convincing finding is that IL-23-specific p19, but 
not IL-12-specific p35 is indispensible for EAE development (Cua et al., 2003).  
If TH17 is the primary encephalitogenic effector, one key question that has not been 
well understood is how TH17 cells induce neuroinflammation in MS and EAE. Given 
CD4+ T cell secret cytokines to orchestrate immune response, it is likely that certain 
effector cytokines produced by TH17 cells are the pathogenic mediators in 
neuroinflammation. So far, the major cytokines produced by TH17 cells are IL-17, 
IL-17F, IL-22 and IL-21. 
IL-17 can induce diverse proinflammatory cytokines and chemokines from a variety 
of target cells, and can recruit neutrophils to the inflammatory tissues (Ye et al., 2001). 
The role of IL-17 in EAE development is controversial. IL-17 neutralization was first 
shown to ameliorate EAE development (Hofstetter et al., 2005a). Then Komiyama et 
al also reported that IL-17 played an important role in the development of EAE 
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(Komiyama et al., 2006). They found delayed onset and reduced disease severity in 
Il17-/- mice. A few years later, Haak et al argued that neither IL-17 nor IL-17F vitally 
contribute to EAE development also using knockout mice as well as T cell-driven 
overexpression of IL-17 mice (Haak et al., 2009). Unlike IL-23 or IL-6-deficient mice, 
which are completely resistant to EAE, IL-17-deficient mice display high incidence 
and comparable maximum score (Cua et al., 2003; Eugster et al., 1998). Therefore, 
the far more critical role of IL-23 and IL-6 in EAE development suggests that the 
increased expression of IL-17 and IL-17F in MS and EAE is a symptom or minor 
effector but not the causal factor in the pathology of autoimmune neuroinflammation.  
IL-22 induces innate immune cells to produce antimicrobial peptides and protects 
hepatocytes from acute liver inflammation (Liang et al., 2006; Zenewicz et al., 2007). 
IL-22 is also reported to mediate IL-23-induced dermal inflammation (Zheng et al., 
2007), whereas it is not required for EAE development (Kreymborg et al., 2007). 
IL-21 is an autocrine cytokine induced by IL-6 in a STAT3-dependent manner (Korn 
et al., 2007; Nurieva et al., 2007; Zhou et al., 2007). IL-21 can in turn amplify TH17 
cells and also increase IL-23R expression. In the context of EAE, Nurieva et al 
showed that loss of IL-21 impaired TH17 generation and protected mice against EAE 
development (Nurieva et al., 2007). However, Sonderegger et al disagreed with this 
view by demonstrating that TH17 generation, their infiltration to the CNS and EAE 
development were not affected at all in either Il21-/- or Il21r-/- mice (Sonderegger et al., 
2008c). It is proposed that IL-6 is sufficient to drive TH17-mediated autoimmunity in 
vivo in the absence of IL-21.  
IL-6 and IL-23 are crucial for TH17 development and TH17-associated autoimmune 
neuroinflammation, a view proved by evidence from independent groups. But none of 
the TH17 hallmark cytokines (IL-17, IL-17F, IL-22 and IL-21) is mandatory for EAE 
development. Then the question is how IL-6 and IL-23 render TH17 
encephalitogenicity and what the true mediator is. Previously, it has been indicated 
that besides the induction of effector cytokines, IL-6 inhibits the generation of Treg 
cells (Korn et al., 2007). IL-6 has a pivotal function in dictating the fate of T cell 
differentiation: TH17 cells with pathogenic potential or Treg cells with suppressive 
capacity. This may partially explain the requirement of IL-6 in EAE development.  
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More than one decade ago, GM-CSF deficient mice were shown completely resistant 
to EAE development (McQualter et al., 2001). But only until recently, GM-CSF is 
considered as the real pathogenic mediator of TH17-mediated autoimmune 
neuroinflammation. GM-CSF was first described to regulate hemopoietic cell 
differentiation into granulocytes and macrophage, but later MG-CSF-deficient mice 
showed no defect in myeloid cell generation (Stanley et al., 1994). GM-CSF is 
produced by several types of cells, including fibroblasts, macrophage, mast cells, 
endothelial cells and T cells (Fleetwood et al., 2005). However, only T cell-specific 
production of GM-CSF is mandatory for EAE development (Ponomarev et al., 2007). 
This study originally highlighted the importance of GM-CSF production by 
autoreactive T cells, but did not figure out the regulatory mechanism of GM-CSF 
expression. Recently, two groups reported that the encephalitogenicity of TH17 cells 
was dependent on IL-23-induced production of GM-CSF (Codarri et al., 2011; 
El-Behi et al., 2011). These findings eventually establish GM-CSF as the pathogenic 
mediator important for recruiting myeloid cells to the CNS and sustaining 
neuroinflammation. Meanwhile, the regulation of GM-CSF expression by IL-23 
further emphasizes the key role of IL-23 in rendering TH17 encephalitogenicity.  
The characterization of GM-CSF as the pathogenic mediator seems to solve all the 
previous questions regarding TH17 encephalitogenicity. But one question rising is that 
GM-CSF is not exclusively expressed in TH17 cells and IL-1β can also induce 
GM-CSF expression in TH1 cells, so how to evaluate the relationship of 
GM-CSF-expressing T cells, IL-17-expressing T cells and IFN-γ-expressing T cells? 
GM-CSF-expressing cells induced more severe EAE disease in adoptive transfer than 
IL-17-expressing T cells or IFN-γ-expressing T cells. Moreover, GM-CSF is even 
thought to mediate a third pathway in EAE development beyond IL-17 and IFN-γ 
pathways (Kroenke et al., 2010).  
In this Chapter, we further address how STAT5 regulates the encephalitogenicity of 
autoreactive T cells, which results in the characterization of a novel helper T cell 
subset featured by GM-CSF secretion.   
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5.2 Results 
5.2.1 Diminished induction of GM-CSF in Stat5-deficient autoreactive CD4+ T 
cells 
Several reports have demonstrated that GM-CSF is the pathogenic mediator of 
encephalitogenic T cells, and it is essential the development of autoimmune 
neuroinflammation. Further studies reveal that IL-23 and GM-CSF build the 
communication between CNS-infiltrating CD4+ T cells and myeloid cells, which is 
critical for sustaining neuroinflammation (Codarri et al., 2011; El-Behi et al., 2011). 
In the Chapter 4, we have shown that T cell-specific deletion of Stat5 results in the 
resistance to EAE induction independent of TH17 and TH1 generation. Based on the 
current information, we hypothesized that STAT5 may regulate GM-CSF expression 
in autoreactive CD4+ T cells. 
To test whether GM-CSF expression was impaired by Stat5 deletion, we isolated 
CD4+ T cells from spleens of Stat5 FF and Stat5 CFF mice during EAE induction and 
stimulated these cells by TCR activation. Intriguingly, we found that GM-CSF mRNA 
expression in Stat5 knockout cells was lower compared with that in wild-type cells, 
suggesting that STAT5 regulates GM-CSF expression in MOG35-55-specific CD4+ T 
cells (Fig. 18a). To further study whether GM-CSF expression in autoreative CD4+ 
cells was regulated by STAT5, splenocytes derived from MOG35-55/CFA-immunized 
Stat5 FF and Stat5 CFF mice were challenged with various concentrations of 
MOG35-55 for 24 h, and the secretion of GM-CSF into the supernatant was measured 
by ELISA. We found that GM-CSF production was increased in a MOG35-55 
concentration-dependent manner in wild-type cells. Stat5 deletion greatly diminished 
the induction of GM-CSF (Fig. 18b). To further address the question raised above, we 
stimulated splenocytes derived from mice during the development of EAE with 
PMA/Ion in the presence of GolgiPlug and examined GM-CSF production by 
intracellular staining and flow cytometry. Cellular analysis was gated on CD4+CD44hi 
population. Although IL-17 expression was enhanced, we observed a significantly 
reduced proportion of GM-CSF+IL-17- and GM-CSF+IL-17+ cells among CD4+CD44hi 
cells in the absence of STAT5 (Fig. 18c). These results indicate that STAT5 may be 
required for GM-CSF induction in autoreactive CD4+ T cells. However, we did not 
find STAT3, an important transcription factor in TH17 differentiation, was important 
for GM-CSF production in CD4+ T cells in the context of EAE (Fig. 18d).  
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We next examined whether GM-CSF expression in the CNS was also diminished 
when STAT5 was abrogated. The spinal cords were harvested for RNA extraction at 
day 14 after MOG35-55/CFA immunization. Strikingly, GM-CSF expression in the 
inflamed CNS was dramatically induced in the EAE mice compared with naïve mice 
(Fig. 18e), suggesting an important role of GM-CSF in neuroinflammation. We found 
indeed GM-CSF expression in Stat5 CFF mice was much lower than that in Stat5 FF 
mice (Fig. 18e). GM-CSF is produced in fibroblasts, macrophage, endothelial cells, T 
cells and several other types of cells (Fleetwood et al., 2005). To validate that the 
GM-CSF in the inflamed CNS was expressed by invaded CD4+ T cells, we isolated 
the mononuclear cells from the CNS of Stat5 FF and Stat5 CFF mice at the peak of 
EAE disease and analyzed GM-CSF expression by intracellular staining and flow 
cytometry. As expected, most GM-CSF+ cells were CD4+ T cells (Fig. 18f), indicating 
the high level of GM-CSF expression in the inflamed CNS attributes to invaded CD4+ 
T cells. In addition, the number of CD4+GM-CSF+ cells in the CNS of Stat5 CFF 
mice was much lower than that of Stat5 FF mice (Fig. 18f).  
Previously, we have showed that at the late stage of EAE development, the immune 
cell infiltration in Stat5 CFF mice was decreased compared with Stat5 FF mice (Fig. 
14b-d). Thus, to exclude the influence from variations of cell infiltrations, we 
measured cytokine production in CNS-infiltrating CD4+ T cells by flow cytometry. 
Although, IL-17 and IFN-γ production by CNS-infiltrating CD4+ T cells was not 
altered by Stat5 deficiency, we detected a reduced induction of CD4+GM-CSF+ cells 
in inflammatory CNS of Stat5 CFF mice compared with control mice (Fig. 18g). 
Further analysis showed a reduced GM-CSF+ percentage among CD4+IL-17+ cells, 
and more significantly among CD4+IFN-γ+ cells (Fig. 18g). In summary, our results 
suggest that GM-CSF induction in CD4+ T cells is regulated by STAT5 and the 
impaired GM-CSF production in the absence of STAT5 could contribute to the 
resistance to EAE. 
  
CHAPTER 5  
	   79 
 
  
CHAPTER 5  
	   80 
Figure 18 Diminished induction of GM-CSF in Stat5-deficient CD4+ T cells. 
(a) Splenic CD4+ T cells were isolated from EAE mice (n=3 per group) and 
stimulated with α-CD3 plus α-CD28 for the analysis of GM-CSF expression by 
RT-PCR 
(b) Splenocytes obtained from MOG-immunized Stat5 FF and Stat5 CFF mice (n=4) 
before disease onset were challenged with MOG at various concentration for 24 hr. 
GM-CSF secretion was measured by ELISA.  
(c) IL-17 and GM-CSF expression by splenic CD4+CD44hi T cells was determined by 
intracellular staining and flow cytometry before disease onset. 
(d) IL-17 and GM-CSF expression by splenic CD4+CD44hi T cells from Stat3 FF and 
Stat3 CFF EAE mice at day 19.  
(e) Spinal cords were obtained from Stat5 FF and Stat5 CFF mice (n=3 per group) at 
day 14 after MOG 35-55 immunization. The mRNA expression of GM-CSF was 
analyzed by RT-PCR. The RT-PCR data were normalized to 18S rRNA, and 
expression of naïve mice was set to 1. 
(f) Mononuclear cells were isolated from the CNS of EAE mice. Cells were 
stimulated with PMA/Ion in the presence of Golgiplug for the analysis of cytokine 
production by flow cytometry.  
(g) IL-17, IFN-γ and GM-CSF expression by CNS-infiltrating CD4+ T cells was 
measured at peak of disease. The percentage of GM-CSF+ cells among IL-17+ and 
IFN-γ+ cells was calculated (bottom right).  
Data represent two independent experiments. *p<0.05, ***p<0.0005. 
  
CHAPTER 5  
	   81 
5.2.2 STAT5-mediated induction of GM-CSF expression is independent of IL-23 
and IL-1β signaling 
STAT family proteins are well recognized for their crucial roles in transmitting 
cytokine signals, specifying helper T cell lineages, and inducing effector cytokine 
expression. We next investigated the cytokine signals that activate STAT5 and induce 
GM-CSF expression.  
IL-23 and IL-1β have been characterized to drive GM-CSF expression in TH17 cells 
(Codarri et al., 2011; El-Behi et al., 2011), so we wondered whether STAT5 was the 
downstream molecule transmitting IL-23 and IL-1β signals. To test this, we purified 
CD4+ T cells and differentiated the cells with TGF-β and IL-6, which induced the 
expression of IL-23R and IL-1R1. Then cells were stimulated by various cytokines 
for the detection of STAT5 activation by pophspho-STAT5a/b (Y694) specific 
antibody and immunoblotting. We found neither IL-23 nor IL-1β potently activated 
STAT5 (Fig. 19a). However, IL-23 can activate STAT3 to a less extent compared 
with IL-6 (Fig. 19a).  
Next we examined whether STAT5 indirectly regulated GM-CSF expression by 
controlling the expression of IL-23R and IL-1R. Splenic CD4+ T cells were isolated 
from Stat5 FF and Stat5 CFF mice during EAE induction for analyzing the mRNA 
expression of IL-23R and IL-1R, but we did not detect any deficiency in the absence 
of STAT5 (Fig. 19b). In fact, IL-23R was found increased in Stat5-knockout CD4+ T 
cells (Fig. 19b), consistent with the previous in vitro data. Together, these data show 
that the ability of STAT5 to induce GM-CSF is likely independent of IL-23 and IL-1β 
signaling. 
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Figure 19 STAT5 does not mediate IL-23 or IL-1β signaling. 
(a) Purified CD4+ T cells were cultured with TGF-β and IL-6 for 3 days, followed by 
starvation for 6 hr. Then cells were treated with various cytokines for 30 min, and 
pSTAT3 and pSTAT5 were determined by immunoblotting. STAT3 and STAT5 were 
further detected after stripping.   
(b) Splenic CD4+ T cells were isolated from EAE mice (n=3 per group) before disease 
onset and stimulated with anti-CD3 and anti-CD28 for the analysis of IL-23R and 
IL-1R1 expression by RT-PCR. *p<0.05.  
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5.2.3 IL-7-STAT5 signaling induces GM-CSF expression in autoreactive CD4+ T 
cells and contributes to neuroinflammation 
Both IL-23 and IL-1β were not potent stimulators of STAT5 activation. In contrast, 
we found IL-2 and IL-7 strongly activated STAT5 by inducing tyrosine 
phosphorylation (Fig. 19a). Therefore, we further examined the effect of these two 
cytokines on GM-CSF induction in autoreactive T cells. Splenocytes derived from 
MOG35-55\CFA-immunized wild-type mice were challenged with MOG35-55 alone, 
plus IL-2 or IL-7. GM-CSF and IL-17 production by CD4+ T cells were analyzed by 
intracellular cytokine staining and flow cytometry. As shown in Fig. 20a, IL-2 had 
modest effects on GM-CSF production. In contrast, IL-7 significantly promoted 
GM-CSF production in both IL-17- and IL-17+ CD4+CD44hi T cells (Fig. 20b). 
However, the frequency of CD4+IL-17+ cells was not affected by the exposure to IL-7 
(Fig. 20b). Furthermore, IL-7 carried out this function in a STAT5-dependent manner, 
as Stat5 deletion abrogated its effect on GM-CSF expression as assessed by 
intracellular cytokine staining and ELISA (Fig. 20b, lower panels, and 20c). Notably, 
the basal level of GM-CSF expression upon MOG35-55 challenge was consistently 
reduced in Stat5-knockout cell compared with wild-type cells (Fig. 20b,c).  
We found IL-7Rα was expressed in both CD62LhiCD44loT cells and CD62LloCD44hi 
T cells (data not shown), suggesting IL-7 may directly act on CD4+ T cells by 
regulating GM-CSF expression in the context of EAE. We therefore sorted 
CD62LhiCD44lo and CD62LloCD44hi T cells from Stat5 CFF mice and littermate 
controls during EAE development, and then activated cells in the presence or absence 
of IL-7. As shown in Fig. 20d, CD62LloCD44hi T cells potently expressed GM-CSF, 
while CD62LhiCD44lo T cells expressed GM-CSF leveling 30-fold lower amounts. 
STAT5 deletion resulted in reduced basal GM-CSF production in CD62LloCD44hi T 
cells. As expected, IL-7 promoted GM-CSF expression in both subsets of CD4+ T 
cells in a STAT5-dependent manner (Fig. 20d).  
To examine the contribution of IL-7-induced GM-CSF expression in autoreactive 
CD4+ T cells to EAE development, we treated mice with IL-7Rα-specific antibody 
(clone SB/14) during EAE development. As expected, the treatment resulted in a 
significant reduction of disease severity, which was accompanied with reduced CNS 
inflammation (Fig. 21a,b). Our result is consistent with previous report that 
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IL-7Rα-deficient mice were resistant to EAE development (Walline et al., 2011). In 
agreement with previous report (Lee et al., 2012), this neutralizing antibody did not 
have T cell depleting activity (Fig. 21c). Notably, the blockade of IL-7 signaling 
resulted in decreased GM-CSF expression in CNS-infiltrating CD4+ T cells (Fig. 
21d-f).  In summary, our findings indicate that IL-7 induces STAT5-dependent 
GM-CSF expression in autoreactive CD4+ T cells, which contributes to the 
development of neuroinflammation. 
In addition, our data suggest that IL-7-STAT5 signaling may induce a novel helper T 
cell subset independent of TH1 or TH17, which is featured by the production of 
GM-CSF during the development of EAE. We will present the evidence to 
characterize GM-CSF-expressing cell as a distinct helper T cell subset in Chapter 6.  
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Figure 20 IL-7-induced STAT5 activation promotes GM-CSF expression in 
autoreactive CD4+ T cells. 
(a) Splenocytes were obtained from MOG35-55/CFA-immunized wild-type mice at day 
7, and challenged with MOG35-55 (20 µg/ml) in the absence or presence of IL-2 (100 
IU/ml) for 48 hr. After washing, cells were restimulated with PMA/Ion in presence of 
Golgiplug for 4 hr. GM-CSF and IL-17 production by CD4+CD44hi T cells were 
analyzed. Data represent two independent experiments with two to three mice per 
group. 
(b) Stat5 FF and Stat5 CFF mice were immunized with MOG35-55/CFA for 7 days. 
Splenocytes were obtained and stimulated with MOG35-55 alone or plus IL-7 (20 ng/ml) 
for 48 hr. GM-CSF and IL-17 production was analyzed as in a. Data represent two 
independent experiments. 
(c) GM-CSF production as in b was measured by ELISA. 
(e) Splenic CD62LhiCD44lo and CD62LloCD44hi T cells from MOG35-55/CFA 
-immunized mice were sorted out. Cells were stimulated with anti-CD3 and 
anti-CD28 in the absence or presence of IL-7 for 4 h and then harvested for the 





CHAPTER 5  
	   87 
 
 
CHAPTER 5  
	   88 
Figure 21 IL-7Rα neutralization ameliorates EAE. 
(a) Clinical scores of EAE mice (n=5) treated with anti-IL-7Rα or normal IgG given 
every other day from day 5 after 2nd immunization, as indicated by arrows.  Data 
represent two independent experiments.  
(b) Spinal cord sections were obtained from EAE mice at day 11 after 2nd 
immunization. Immune cell infiltration was assessed histologically. Images shown are 
representative of three individuals per group. Scale bars, 200 µm (top), 50 µm 
(bottom). 
(c) The percentages of CD4+ and CD8+ T cells in spleens of EAE mice. Data 
represent two independent experiments. 
(d,e) The frequencies of GM-CSF+, IL-17+ and IFN-γ+ cells among CD4+ T cells in 
the CNS of EAE mice receiving different treatment. 
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5.2.4 Different roles of IL-7 and IL-23 in the induction of GM-CSF-expressing 
TH cells 
IL-23 is thought to be crucial for stabilizing TH17 differentiation and endowing TH17 
with encephalitogenicity (Cua et al., 2003; Langrish et al., 2005). The characterization 
of GM-CSF as an IL-23-induced pathogenic mediator further supports the central role 
of IL-23 in determining autoimmune neuroinflammation. However, we have showed 
that IL-7-STAT5 signaling induces GM-CSF expression in autoreactive CD4+ T cells 
independent of IL-23 signaling. One major question is how IL-7 and IL-23 endow 
CD4+ T cells with the ability to produce GM-CSF in the context of EAE 
development.  
Our preliminary data showed that GM-CSF expression in the spinal cord of EAE mice 
was dramatically induced at day 8 (before onset) after MOG35-55/CFA immunization 
compared with naïve mice (Fig. 22). This increased GM-CSF expression was 
attributed to the presence of GM-CSF-expressing CD4+ T cells demonstrated by our 
previous data and the observation that GM-CSF expression in the spinal cord 
remained unchanged at day 4 post immunization (Fig. 22). Surprisingly, it appeared 
that IL-23 expression in the spinal cord was not induced at day 8 (Fig. 22), indicating 
that GM-CSF induction precedes IL-23 induction in the CNS. Together with our 
previous data that GM-CSF-expressing CD4+ T cells was induced in the periphery by 
MOG35-55/CFA immunization, we hypothesized that peripheral GM-CSF-expressing 
CD4+ T cells migrated to the CNS and initiated neuroinflammation by producing 
GM-CSF independent of IL-23. However, IL-23 expression in the CNS was gradually 
induced by GM-CSF after day 8 (Fig. 22), which played a crucial role in reinforcing 
GM-CSF expression in the effector phase of EAE development.   
Consistent with the resistance to EAE induction, Stat5 CFF mice showed constantly 
lower level of GM-CSF expression in the spinal cord than that of Stat5 FF mice (Fig. 
22). At day 8, GM-CSF expression in Stat5 CFF mice already showed a significantly 
reduced induction compared with littermate control, whereas IL-17 induction seemed 
even higher (Fig. 22). These results further confirm that STAT5 mediates GM-CSF 
expression independent of IL-23 and also indicate that the expression of GM-CSF and 
IL-17 in autoreactive CD4+ T cells was differentially regulated.  
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It has been recognized that IL-7 and IL-7Rα variant was increased in the serum and 
cerebral-spinal fluid of MS patients compared with healthy control. Furthermore, a 
previous study using mouse model showed that the activation of TLR signaling 
induced an increase of serum IL-7 derived from hepatocytes, and the increased IL-7 
further regulated T cell response (Sawa et al., 2009). Therefore, we speculate that the 
generation of GM-CSF-expressing CD4+ T cells is induced by IL-7 in a 
STAT5-dependent manner at the induction phase of EAE development. More studies 
need to be performed to test this hypothesis.  
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Figure 22 Time-course analysis of cytokine expression in the spinal cord during 
EAE development. 
Stat5 FF and Stat5 CFF mice were immunized with MOG35-55/CFA. The spinal cords 
(3-5 mice per group) were harvested for RNA extraction at day 4, day 8, day 14 and 
day 21. The mRNA expression of cytokines was measured by RT-PCR. The RT-PCR 
data were normalized to 18s rRNA, and expression in naïve Stat5 FF mice was set to 
1. *p<0.05.  
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5.2.5 Stat5-deficient CD4+ T cells retain the capacity to induce colitis 
The finding from the EAE model prompted us to test whether STAT5-dependent T 
cell differentiation, particularly GM-CSF-expressing T cells, also lacked 
pathogenicity in other T cell-mediated inflammatory diseases. TH17 and TH1 cells 
play important roles in chronic intestinal inflammation. Therefore, we assessed the 
pathogenic potential of STAT5-deficient autoreactive CD4+ T cells in a colitis model, 
in which Rag2-/- mice were reconstituted with Stat3-/-, Stat5-/- or control 
CD4+CD25-CD45RBhi naïve T cells. Development of colitis was monitored weekly 
by measuring body weight. Consistent with a previous report (Durant et al., 2010), 
mice reconstituted with Stat3-/- T cells continued to gain weight, whereas mice that 
received Stat5-/- T cells lost weight (Fig. 23a). Mice that received Stat5-/- T cells had 
enlarged spleens and mesenteric lymph nodes (MLNs) comparable to those of control 
mice (Fig. 23b). Morphological analysis showed obvious signs of colonic 
inflammation (colon thickening) in mice received WT and Stat5-/- T cells but not 
Stat3-/- T cells (Fig. 23c). 
To further confirm clinical signs of colitis, we evaluated colonic inflammation 
histologically. Mice that received Stat5-/- T cells developed marked inflammation in 
the colon at 8 weeks, with the signs of increased bowel wall thickness and 
inflammatory cell infiltrate (Fig. 23d,e). In contrast, mice reconstituted with Stat3-/- T 
cells had no or limited colonic inflammation (Fig. 23d,e).  
To analyze the cell composition in T cell-transfer colitis, we isolated cells from 
mesenteric lymph nodes (MLNs) and colonic lamina propria lymph nodes (LPLs) of 
Rag2-/- mice 8 weeks after reconstitution. Although both CD11b+ and CD4+ cell 
proportions showed no difference in MLNs, there was an obvious reduction of CD4+ 
cell proportion in LPLs of Rag2-/- mice reconstituted with Stat3-/- T cells (Fig. 24a). 
Consistent with clinical and histological data, Rag2-/- mice reconstituted with Stat5-/- 
T cells had comparable CD11b+ and CD4+ cells to those of control mice in both 
MLNs and LPLs (Fig. 24a). In agreement with a previous report (Durant et al., 2010), 
we also found dramatically reduced numbers of IL-17-producing CD4+ T cells in 
LPLs of Rag2-/- mice reconstituted with Stat3-/- T cells (Fig. 24b). IFN-γ is one of the 
cytokines commonly induced in colitis and implicated in the pathogenesis of 
inflammatory bowel disease (IBD). However, we did not observe any decrease in the 
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proportion of IFN-γ-producing CD4+ T cells in LPLs of mice that received Stat3-/- T 
cells (Fig. 24b). There was no defect in both IL-17 and IFN-γ production by CD4+ T 
cells in LPLs of mice reconstituted with Stat5-/- T cells (Fig. 24b). However, we 
detected a significant reduction in GM-CSF-expressing T cells in the absence of 
STAT5 when transferred into Rag2-/- mice (Fig. 24b), indicating that 
GM-CSF-secreting T cells might not play an important role in this model. This view 
was further supported by the observation that although there were comparable 
GM-CSF+ T cells between Stat3-/- and WT transfer, Stat3-/- CD4+ T cells failed to 
induce colitis. Thus, our data demonstrate that Stat5-/- CD4+ T cells retain the capacity 
to induce colonic inflammation in this colitis model, which may be independent of 
GM-CSF-expressing cells. 
  
CHAPTER 5  




CHAPTER 5  
	   95 
Figure 23 STAT5 is not required in T cell-mediated colitis. 
(a) Rag2-/- mice (3-5 mice per group) were reconstituted with CD4+CD25-CD45RBhi 
naïve T cells derived from WT, Stat3 FF or Stat5 FF mice. Body weight loss was 
monitored and calculated over 7 weeks. Data are representative of two independent 
experiments.  
(b) Systemic inflammation was assessed by comparing size of spleen and MLNs at 8 
weeks. 
(c) Morphology of colon tissues obtained from reconstituted Rag2-/- mice at 8 weeks. 
(d,e) Colonic inflammation was assessed histologically. The representative 
histological micrographs were shown at two different magnifications, 25X in c and 
200X in d.  
*p<0.05, **p<0.005. 
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Figure 24 Impaired induction of GM-CSF in Stat5-deficient CD4+ T cells in the 
inflamed colon tissues. 
(a) The proportions of CD4+ T cells and common myeloid marker CD11b+ cells in 
MLNs and LPLs were analyzed by flow cytometry.  
(b) IL-17, IFN-γ and GM-CSF production by CD4+ T cells in LPLs was measured by 
intracellular cytokine staining and flow cytometry.  
Data are representative of at least 3 mice per group. *p<0.05.  
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5.3 Discussion 
It has been debated whether there is a decisive and essential subset of reactive T cells 
for neuroinflammation. The discovery of TH17 cells and demonstration of their 
extensive roles in inflammation have led to the hypothesis that TH17 cells are the 
major effectors for both peripheral inflammation and neuroinflammation (Becher and 
Segal, 2011; Goverman, 2009; Littman and Rudensky, 2010). However, growing data 
have showed that neither T cell–driven ectopic of IL-17 nor complete loss of IL-17 
and other TH17 related cytokines had a major impact on the development of 
neuroinflammation (Haak et al., 2009; Kreymborg et al., 2007). What signaling 
pathways program naïve T cells into a reactive and pathogenic T cell lineage 
specifically required for neuroinflammation remains unclear. 
The recognition that IL-23 is an essential mediator for autoimmune encephalomyelitis 
significantly contributes to our understanding of this disease (Becher et al., 2003; Cua 
et al., 2003). IL-23 mediates terminal differentiation of the TH17 subset of helper T 
cells and the presence of the IL-23 receptor on T cells facilitated infiltration of TH17 
cells into the CNS (Gyulveszi et al., 2009; McGeachy et al., 2009). 
However, our findings suggest that the STAT5-mediated induction of EAE is likely 
independent of IL-23 (Fig. 19). It is IL-7, but not IL-23 that activated STAT5 for 
induction of GM-CSF (Fig. 20). STAT5 regulates gene expression of GM-CSF, and 
loss of STAT5 resulted in impaired GM-CSF production in CD4+ T cells during EAE, 
despite increased IL-23R expression. This conclusion is consistent with previous 
observations that IL-7 is necessary for EAE induction (Liu et al., 2010; Walline et al., 
2011). IL-7Rα has been characterized to be associated with MS in humans (Gregory 
et al., 2007; Lundmark et al., 2007), and an anti-IL-7Rα antibody inhibited induction 
of EAE, whereas anti-IL-23 receptor antibodies that worked well for peripheral 
inflammation such as psoriasis, failed in treating MS (Croxford et al., 2012). Our data 
and previous observations thus suggest that neuroinflammation may require a specific 
pathway and a unique CD4+ T cell subset.  
More importantly, it is known that IL-23 does not drive cell differentiation from naïve 
CD4+ T cells, probably due to the fact that naïve CD4+ T cells do not express their 
receptors (Croxford et al., 2012). IL-23 might maintain GM-CSF-secreting CD4+ T 
cell phenotype in the effector phase of EAE. In contrast, we showed that IL-7-STAT5 
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signals could program naïve T cells to produce GM-CSF (Fig. 20d and data in 
Chapter 6), thus further indicating this is a unique pathway independent of IL-23 for 
generation of GM-CSF-expressing cells. We further demonstrated that Stat5-/- naïve 
CD4+ T cells induce severe colitis similar to wild-type controls in a T cell transfer 
colitis model, although GM-CSF-expressing cells were reduced in the inflamed colitis. 
This result further indicates that this IL-7-STAT5-GM-CSF programmed CD4+ T cell 
subset might have restricted functions in autoimmunity that includes 
neuroinflammation. 
Increased level of IL-7 and IL-7Rα variant is found in the serum and cerebral-spinal 
fluid of MS patients. In a mouse model, the activation of TLR signaling induced an 
increase of serum IL-7 derived from hepatocytes, and the increased IL-7 regulated T 
cell response (Sawa et al., 2009). On the contrary, IL-23 is produced by CNS-resident 
cells to control T cell encephalitogenicity in the effector phase of EAE (Becher et al., 
2003). Our data show that GM-CSF induction in the spinal cord precedes IL-23 
induction, which happens at effector phase of EAE development. We propose a 
three-step model to interpret the roles of IL-7 and IL-23 in EAE development: 
MOG35-55/CFA immunization in mice induces IL-7 expression, which drives the 
generation of self-antigen-specific GM-CSF-expressing helper T cells; 
GM-CSF-expressing helper T cells migrate to the CNS where they secret GM-CSF to 
recruit peripheral myeloid cells and induce IL-23 expression in recruited myeloid 
cells and CNS-resident cells; IL-23 reinforces GM-CSF expression in T cells to 
sustain neuroinflammation (Fig. 25).  
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Figure 25 A working model: IL-7 and IL-23 endow GM-CSF-expressing helper 
T cell with encephalitogenicity. 
IL-7 drives naïve CD4+ T cell differentiation into GM-CSF-expressing helper T cells 
with specificity to myelin-antigen. IL-23 reinforces GM-CSF express in the CNS 
through forming a positive feed-back loop. 
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Chapter 6 The differentiation programme of a distinct 
GM-CSF-expressing helper T cell subset 
 
6.1 Introduction 
CD4+ helper T cells play an indispensible role in host defense against various 
pathogens by orchestrating adaptive immune responses. But the aberrant T cell 
differentiation and activation results in autoimmune diseases and inflammatory 
disorders. Cytokine milieus are well known for their roles in determining the lineage 
commitment of naïve CD4+ T cells. So far, CD4+ T cells are committed to 
differentiate into at least five major subsets: TH1, TH2, TH17, iTreg cells and TFH. 
STAT family proteins transmit cytokine signals and are crucial for inducing 
lineage-specific transcription factors, which program lineage differentiation.  
Recently, the concept of lineage plasticity of CD4+ T cells has emerged. For instance, 
the simultaneous secretion of IFN-γ and IL-17 is commonly occurred (Lee et al., 2009; 
Wilson et al., 2007), which was also observed in our experiments with EAE mice. 
TH1 cells can produce IL-13 under certain circumstances (Hayashi et al., 2007). Treg 
cells can extinguish Foxp3 expression and acquire the ability to secret 
proinflammatory cytokines (Xu et al., 2007; Zhou et al., 2009). These evidences argue 
that the fate of CD4+ T cell lineage is not fixed and that committed T cells can change 
the properties according to the environmental clues.  
GM-CSF is a proinflammatory cytokine, which can be produced by fibroblasts, 
macrophages, endothelial cells, T cells and several other types of cells (Fleetwood et 
al., 2005). Overexpression of GM-CSF in transgenic mice causes inflammation in 
multiple organs (Lang et al., 1987), while loss of GM-CSF or GM-CSF blocking with 
neutralizing antibody protects mice against autoimmune diseases (McQualter et al., 
2001; Ponomarev et al., 2007; Sonderegger et al., 2008b). Almost two decades ago, it 
was found that CD28 costimulation activated NF-κB signaling pathway and induced 
GM-CSF expression in T cells (Kahn-Perles et al., 1997). The importance of NF-κB 
signaling pathway in GM-CSF induction is demonstrated by c-rel mutant T cells 
which exhibit defect in producing GM-CSF (Gerondakis et al., 1996). In addition, a 
NF-κB/Sp1 binding region at the promoter of Csf2 locus has been identified essential 
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for chromatin remodeling and gene transcription (Cakouros et al., 2001). NFAT also 
contributes to CD28 costimulation-induced GM-CSF expression (Shang et al., 1999). 
But in the first ten years for this century, there was little progress in understanding the 
regulatory mechanism of GM-CSF expression and the specific function of T 
cell-secreted GM-CSF. Previously it was also not well known what cytokine signals 
regulated GM-CSF expression. Only until recently, IL-23 and IL-1β have been 
demonstrated to promote GM-CSF expression in effector T cells (Codarri et al., 2011; 
El-Behi et al., 2011). However, IL-23 does not likely induce GM-CSF expression in 
naïve CD4+ T cells due to the lack of its receptor. Neither RORγt nor T-bet is required 
for GM-CSF expression. These observations indicate that the generation of 
GM-CSF-expressing T cells may be independent of TH1 and TH17. 
GM-CSF was previously thought a TH1 cytokine required for EAE development 
(Ponomarev et al., 2007). Both IL-23 and GM-CSF are necessary for the development 
of neuroinflammation (Cua et al., 2003; McQualter et al., 2001; Ponomarev et al., 
2007). In addition, GM-CSF has been determined as a pathogenic mediator induced 
by IL-23 in autoreactive CD4+ T cells (Codarri et al., 2011; El-Behi et al., 2011). 
These observations tend to support GM-CSF as a TH17 cytokine. However, there is a 
considerable proportion of GM-CSF+ CD4+ T cells identified as IL-17- cells in our 
data and previous report (Codarri et al., 2011). We also detect the presence of 
GM-CSF+IFN-γ+ T cells in the inflamed CNS (in Chapter 5), consistent with the 
finding that IL-1β can also induce GM-CSF expression in TH1 cells (El-Behi et al., 
2011). So how to evaluate the relationship of GM-CSF-expressing, IL-17-expressing 
and IFN-γ-expressing T cells? Functionally, GM-CSF-expressing T cells induce more 
severe EAE disease in adoptive transfer assay than IL-17-expressing T cells or 
IFN-γ-expressing T cells (Codarri et al., 2011). We have further demonstrated that 
STAT5 differentially regulates the generation of these three populations (see Chapter 
5). We hypothesize that GM-CSF-expressing TH could be a distinct TH subset.  
In this Chapter, we demonstrated that GM-CSF-expressing TH cell differentiation 
from naïve T cell is distinct from TH17 and TH1. Cytokine milieus that required for 
TH17 or TH1 differentiation actually suppress GM-CSF expression. Despite its 
indispensability in TH17 differentiation, IL-6-STAT3 signaling inhibits the 
differentiation of GM-CSF-expressing TH cell. We further confirm the importance of 
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CD28 activation in promoting GM-CSF expression. More importantly, we 
characterize that IL-7-STAT5 signaling programs GM-CSF-expressing TH 
differentiation.  
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6.2 Results 
6.2.1 GM-CSF-expressing TH subset is distinct from TH17 and TH1 
We observed that both IL-17+ and IL-17- CD4+ T cells, and both IFN-γ+ and IFN- γ- 
CD4 T cells expressed GM-CSF in the context of EAE. We also found that STAT5 
differentially regulated the generation of TH17 and GM-CSF-expressing TH cells. We 
therefore investigated the relationship of GM-CSF-expressing TH with TH17 and TH1. 
We polarized naïve CD4+ T cells with plate-bound anti-CD3 and soluble anti-CD28 
under TH1, TH17 (with TGF-β) or alternative TH17 (without TGF-β) conditions. 
Surprisingly, we found that both TH1 and TH17-polarizing conditions suppressed 
GM-CSF-expressing TH differentiation (Fig. 26a,b). There were about 16% GM-CSF+ 
cells detected when naïve CD4+ T cells were activated by anti-CD3 and anti-CD28 
only. Exogenous IL-12 promoted IFN-γ+ cell differentiation, but it remarkably 
inhibited GM-CSF+ cell differentiation. Under both conditions, only a small 
proportion of GM-CSF+IFN-γ+ cells were detected by intracellular cytokine staining 
and flow cytometry (Fig. 26a). We also differentiated naïve CD4+ T cells under both 
conventional TH17-polarizing condition (cTH17, TGF-β + IL-6) and pathogenic 
TH17-polarizing condition (pTH17, IL-6 + IL-23 + IL-1β), but found that either 
condition suppressed GM-CSF-expressing cell differentiation (Fig. 26a,b). Similarly, 
few GM-CSF+IL-17+ cells were detected. On the contrary, IL-12 and IFN-γ 
neutralization promoted GM-CSF+ cell generation (Fig. 26a), consistent with a 
previous report (Codarri et al., 2011). However, IL-23 and IL-1β did not further 
enhance GM-CSF-expressing cell differentiation from naïve CD4+ T cells (Fig. 26a), 
which was consistent with the fact that naïve CD4+ T cells did not express their 
receptors. Under the neutralization condition, IFN-γ+ cells were diminished, which 
could be the reason for the increased GM-CSF-expressing cell differentiation. We 
detected rare GM-CSF+IFN-γ+ and GM-CSF+IL-17+ cells under various conditions in 
vitro (Fig. 26a).  
TGF-β has a dominant suppressive effect on GM-CSF expression (El-Behi et al., 
2011). We further dissected the role of IL-6, an essential cytokine for TH17 
differentiation, in regulating GM-CSF expression. To our surprise, we found IL-6 also 
strongly suppressed GM-CSF-expressing TH differentiation (Fig. 26c), indicating 
STAT3, which is a major downstream molecule of IL-6 signaling, could be a negative 
regulator. To study this question, we purified naïve CD4+ T cells from Stat3 CFF 
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mice for cell differentiation. In the absence of STAT3, cells polarized under 
alternative TH17 condition (with IL-6 but not TGF-β) begun to potently express 
GM-CSF (Fig. 26d). Interestingly, even without exogenous IL-6, STAT3 still 
somehow suppressed GM-CSF-expressing TH differentiation (Fig. 26d). We didn’t 
know the mechanism behind STAT3-mediated suppression of GM-CSF expression at 
this moment. In summary, our data, together with previous reports, support a model 
wherein GM-CSF-expressing TH develops via a lineage distinct from TH17 and TH1. 
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Figure 26 The differentiation of GM-CSF-expressing TH is suppressed by TH1- 
and TH17-polarizing conditions. 
(a-e) Sorted naïve CD4+ T (CD4+CD25-CD62LhiCD44-) cells were primed with 
plate-bound anti-CD3 plus soluble anti-CD28 in the presence of a combination of 
various cytokines and neutralizing antibodies as indicated for 3 days: neutral 
condition, without any cytokine or neutralizing antibody; TH1 condition, IL-12 and 
α-IL-4; TH17 condition, TGF-β, IL-6, α-IFN-γ and α-IL-4; alternative TH17 condition, 
IL-23, IL-1β, α-IFN-γ and α-IL-4. GM-CSF, IL-17 and IFN-γ expression was 
analyzed by intracellular staining and flow cytometry (a,c,d) or RT-PCR (b). The 
RT-PCR data were normalized to β-Actin, and expression under medium condition 
was set to 1. 
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6.2.2 GM-CSF-expressing TH differentiation requires CD28 costimulation 
It has been known that CD28 costimulation activates NF-κB signaling pathway and 
induces GM-CSF expression in T cells (Kahn-Perles et al., 1997). To further explore 
the role of CD28 activation in GM-CSF-expressing TH differentiation, we purified 
naïve CD4+ T cells and primed the cells with anti-CD3 alone or plus soluble 
anti-CD28 for 3 days. Cells without CD28 costimulation did not activate as well as 
those with CD28 costimulation (data not shown). As expected, CD28 costimulation 
dramatically induced GM-CSF expression (Fig. 27a). Previously, we found that both 
plate-bound anti-CD28 and soluble anti-CD28 worked well in TH1 and TH17 
differentiation (data not shown). However, plate-bound anti-CD28 appeared not 
sufficient to support GM-CSF-expressing TH differentiation (Fig. 27b). We further 
studied the relative concentrations of anti-CD3 and anti-CD28 in regulating 
GM-CSF-expressing TH differentiation. It appeared that a combination of higher 
anti-CD3 with lower anti-CD28 concentration favored GM-CSF expression (Fig. 
27c).  
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Figure 27 CD28 activation is necessary for GM-CSF expression. 
(a) Sorted naïve CD4+ T (CD4+CD25-CD62LhiCD44-) cells were primed with 
plate-bound anti-CD3 alone or plus soluble anti-CD28 for 3 days, and GM-CSF 
expression was measured by intracellular cytokine staining.  
(b) Naïve CD4+ T cells were primed with plate-bound anti-CD3 plus plate-bound 
anti-CD28 or soluble anti-CD28 for 3-4 days. GM-CSF expression was measured by 
intracellular cytokine staining and flow cytometry. 
(c) Naïve CD4+ T cells were primed with various concentrations of plate-bound 
anti-CD3 and soluble anti-CD28 for 3-4 days. GM-CSF expression was measured by 
intracellular cytokine staining and flow cytometry. 
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6.2.3 IL-7-STAT5 signaling programs the differentiation of GM-CSF-expressing 
TH subset 
Next, we investigated the cytokine signals promoting GM-CSF-expressing TH 
differentiation. Our previous data suggest that IL-7 may promote GM-CSF expression 
in both naïve and effector CD4+ T cells (Fig. 20d). Thus, we polarized naïve CD4+ T 
cells in the presence of IL-7, and found that exogenous IL-7 promoted 
GM-CSF-expressing TH differentiation in a dosage-dependent manner (Fig. 28a). 
However, we found IL-2, a cytokine also signaling through γc receptor, had modest 
effects on the differentiation of GM-CSF-expressing TH (Fig. 28b).  
To confirm that STAT5 mediated IL-7 function in GM-CSF expression, we isolated 
wild-type and Stat5-knockout naïve CD4+ T cells for differentiation in vitro. By 
examining the proportion of GM-CSF+ cells and GM-CSF cytokine secretion in the 
supernatant medium, we found that loss of STAT5 abrogated the effect of IL-7 on 
promoting the differentiation of GM-CSF-expressing TH cells (Fig. 29a,b). 
Accordingly, IL-7 potently induced STAT5 activation by tyrosine phosphorylation 
(Fig. 29c). However, in Stat5-deficient CD4+ T cells, pY694-STAT5 was below 
undetectable level (Fig. 29c). These results demonstrate that IL-7 promotes 
GM-CSF-expressing TH differentiation in a STAT5-dependent manner.  
STAT5 plays a dual role in both signaling transduction and activation of gene 
expression. Bioinformatics analysis showed two putative STAT5 binding sites 
locating near the transcription starting site (TSS) of Csf2 locus (Fig. 29d, left). To 
further examine the regulation of GM-CSF expression by IL-7-STAT5 signaling, a 
ChIP assay was performed using CD4+ T cells stimulated with IL-7. We found that 
STAT5 directly bound the promoter region (site 1) of the Csf2 gene (Fig. 29d, right), 
and this binding was abrogated in Stat5-deficient CD4+ T cells. The positive STAT5 
ChIP signal in STAT5-deficient cells compared with IgG may be due to the 
insufficient purity of CD4+ T cell or some cross-reactivity of STAT5 antibody. These 
data indicate that STAT5 may transcriptionally activate GM-CSF expression. 
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Figure 28 IL-7 but not IL-2 promotes GM-CSF-expressing TH differentiation. 
(a) Sorted naïve CD4+ T (CD4+CD25-CD62LhiCD44-) cells were primed with 
plate-bound anti-CD3 and soluble anti-CD28 in the presence of various 
concentrations of IL-7 for 3 days. GM-CSF expression was measured by intracellular 
cytokine staining and flow cytometry. 
(b) Naïve CD4+ T cells were primed with plate-bound anti-CD3 and soluble 
anti-CD28 in the presence of IL-2 (50 ng/ml) or α-IL-2 (10 µg/ml) for 3 days. 
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Figure 29 IL-7-induced STAT5 activation directly induces GM-CSF expression. 
(a,b) Wild-type and Stat5-knockout naïve CD4+ T cells were primed with plate-bound 
anti-CD3 and soluble anti-CD28 in the presence of IL-7 (5 ng/ml) for 4 days. 
GM-CSF expression was measured by flow cytometry (a) or ELISA (b). 
(c) Wild-type and Stat5-knockout CD4+ T cells were stimulated with IL-7 for 30 min 
and the activation of STAT5 was detected by immunostaining with antibody against 
pY694-STAT5.  
(d) Putative STAT5 binding sits near TSS of Csf2 locus (left). The ChIP assay was 
performed with wild-type and Stat5-knockout CD4+ T cells using normal IgG or 
STAT5-specific antibody. The binding of antibodies to Csf2 promoter region was 
detected by RT-PCR (right).  
*p<0.05.  
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6.3 Discussion 
In this chapter, we have demonstrated that the differentiation of GM-CSF-expressing 
CD4+ T cell is distinct from TH1 and TH17. Furthermore, we characterize IL-7-STAT5 
signaling promotes the differentiation of this new subset (summarized in Fig. 30).  
CD28 is characterized as a co-receptor for TCR complex and plays a crucial role in T 
cell activation. Previously it has been known that CD28 costimulation is important for 
GM-CSF expression in CD4+ T cells (Kahn-Perles et al., 1997). Furthermore, CD28 
costimulation enhances the acquisition of various effector cell types. For instance, 
CD28 activation is required for IL-4 and IL-17 expression (Lenschow et al., 1996; 
Park et al., 2005). Therefore, CD28 costimulation is a general signal required for the 
induction of various cytokines.  
Cytokines which signals though JAKs-STATs pathway play a crucial role in inducing 
the expression of lineage-specific effector cytokine. Recently, IL-23 and IL-1β have 
been demonstrated to promote GM-CSF expression in effector T cells (Codarri et al., 
2011; El-Behi et al., 2011). However, IL-23 and IL-1β do not likely induce GM-CSF 
expression in naïve CD4+ T cells due to the lack of their receptors. Whether there is a 
cytokine signal directly acting on naïve CD4+ T cell to drive GM-CSF-expressing TH 
cell differentiation remains unknown.  
When certain cytokine milieu drives TH differentiation toward one specific lineage, 
the fates of other lineages are usually suppressed. For instance, IL-12, a cytokine 
crucial for TH1 differentiation, inhibits TH2 and TH17 differentiation. We have 
examined the effect of IL12 and IL-6 during naïve T cell stimulation, and found that 
both cytokines actually suppressed GM-CSF-expressing TH differentiation. So we 
reasoned that GM-CSF-expressing TH could be a new lineage different from TH1 and 
TH17. Functionally, this new GM-CSF-expressing TH lineage appears specifically 
important for the development of autoimmune neuroinflammation. Then what are the 
cytokine signals and transcription factors that program this lineage differentiation? 
Similar to IL-23 and IL-1β, IL-7 enhances GM-CSF production in effector T cells 
(see Chapter 5). But more importantly, we realized that naïve CD4+ T cells highly 
expressed IL-7 receptor and further showed that IL-7 can directly increased GM-CSF 
expression in naïve CD4+ T cells (Fig. 20d). These results suggest IL-7 could be a 
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cytokine driving GM-CSF-expressing TH differentiation. We confirmed this 
speculation by showing that IL-7 promoted naïve CD4+ T cell differentiation into 
GM-CSF-expressing TH upon TCR activation in vitro. Furthermore, STAT5 was 
characterized as a transcription factor activated by IL-7 to transcribe GM-CSF 
expression. TH subset usually exhibits a unique gene expression profile, thus it worth 
studying whether GM-CSF-expressing TH has other specific properties. Since 
GM-CSF+IL-17+ and GM-CSF+IFN-γ+ are present in the context of EAE, the 
plasticity of GM-CSF-expressing TH should be further studied.   
 
 
Figure 30 The differentiation programme of a novel GM-CSF-expressing TH 
subset. 
T cell receptor (TCR) activation by its cognate antigen and CD28 co-stimulation drive 
naïve CD4+ T cells differentiation into effector T cells. IL-7 signaling promotes the 
differentiation of GM-CSF-expressing TH cells, which is suppressed by IL-12 (TH1 
cytokine), IL-6 and TGF-β (TH17 cytokines). 
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CHAPTER 7 GENERAL DISCUSSION 
 
CD4+ T cells are crucial players in the host defense against various pathogens by 
orchestrating adaptive immune responses. However, the aberrant T cell response 
could result in autoimmunity and tissue damage. Activated CD4+ T cell are 
committed to differentiate into different effector cells, determined by extracellular 
cytokine milieu. STAT proteins have essential role in transmitting cytokine signals 
and therefore are certainly crucial for CD4+ T cell lineage commitment. In Chapter 3, 
we studied the regulation of TH17 differentiation by IL-2, with focus on the IL17 
expression. In Chapter 4, we characterized an unexpected role of STAT5 in EAE 
development. In Chapter 5, we demonstrated that STAT5 activated by IL-7 induced 
GM-CSF expression by autoreactive helper T cells, which was necessary for the 
development of neuroinflammation. In Chapter 6, we presented evidence showing 
GM-CSF-expressing cells could be a novel helper T cell subset programmed by 
IL-7-STAT5 signaling. In this Chapter, we will further discuss on how our findings 
challenge current knowledge of autoimmune T cell responses in neuronal 
demyelinating disease.  
 
Direct or indirect suppression of IL-17 expression by IL-2-STAT5 signaling 
There is no doubt that STAT3 and STAT5 play the opposite roles in TH17 
differentiation, particularly in regulating IL-17 expression. The deletion of STAT3 
abrogates TH17 generation due to the unresponsiveness to IL-6, which was reported 
previously (Yang et al., 2007a) and reproduced in our study. In the contrast, IL-2 
suppresses TH17 generation in a STAT5-dependent manner. Yang and colleagues 
proposed that STAT3 and STAT5 competed with each other for binding to multiple 
common sites across Il17-Il17f locus, depending on their relative strength of 
activation by respective cytokines (Yang et al., 2011). In their model, the binding of 
STAT5 to those sites results in gene silencing by recruiting histone modification 
complex. This means IL-2-induced STAT5 activation guides a direct switch-off of 
promoter activity at Il17-Il17f locus. However, we observed that IL-17F expression 
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was not suppressed by IL-2 under TH17-polarizing condition. Functionally, IL-17 and 
IL-17F are quite similar, both of which can induce the expression of diverse 
proinflammatory cytokines from a variety of cells (Weaver et al., 2007). However, 
there are also likely to be nonredundant functions suggested by their preferential 
binding affinity to different members of IL-17R family (Weaver et al., 2007). It is 
interesting to study how these two closely related genes are differentially regulated by 
extracellular cytokines such as IL-2. STAT5 is usually considered as a transcriptional 
activator, so we wondered whether there was other mechanism behind 
STAT5-mediated suppression of IL-17 expression.  
To address this question, we analyzed the transcript profile during TH17 
differentiation and the regulation by IL-2 using RNA-Seq. Dynamic analysis of gene 
expression showed IRF4 and IRF8 were quickly induced upon T cell activation. 
Previously, IRF4 is characterized crucial for TH17 differentiation (Brustle et al., 2007; 
Huber et al., 2008; Kwon et al., 2009). But the role of other IRFs remains unclear. 
IRF8 can act as activator or suppressor depending on the presence the co-activator. 
IRF8 alone blocks the activities of other IRFs (Lohoff and Mak, 2005). We found 
IRF8 expression was rapidly increased when naïve T cells were primed into TH17 
lineage, indicating IRF8 may be involved in TH17 differentiation. Recently, the 
function of IRF8 in TH17 cells was revealed by conditional gene targeting in T cells 
(Ouyang et al., 2011). In that study, loss of IRF8 resulted in more efficient generation 
of TH17 cells and rendered the mice more susceptible to autoimmune intestinal 
inflammation. Collectively, these data led us examine whether IRF8 could be a target 
that contributed to the suppressive effect of IL-2. Indeed, we observed that the 
exposure to IL-2 sustained IRF8 expression at higher level during TH17 
differentiation. Furthermore, IRF8 mRNA expression in TH17 cells was upregulated 
by IL-2 within 30 min, suggesting IL-2 signals may directly induce IRF8 transcription. 
We further confirmed this by ChIP assay and luciferase assay, which strongly argues 
that STAT5 activated by IL-2 transcribes IRF8 expression. Therefore, we conclude 
that besides mediating a direct silencing of IL-17 expression, STAT5 activated by 
IL-2 induces IRF8 expression, which is able to further suppress IL-17 expression. 
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Stat5 conditional knockout mice are resistant to EAE despite enhanced TH17 
generation 
TH17 has been considered as a major effector in autoimmune disorders. The 
antagonistic function of STAT5 in TH17 differentiation led us to hypothesize that loss 
of STAT5 in CD4+ T cells would render mice more susceptible to autoimmune 
diseases. In agreement of this, Stat5-deficient mice lose immune tolerance and 
develop autoimmunity in multiple organs (Snow et al., 2003). To further test our 
hypothesis with specific autoimmune disease model, we induced EAE in Cd4-Cre; 
Stat5 f/f mice, where Stat5 is specifically deleted in T cell compartment. Strikingly, 
Stat5 conditional deletion mice were resistant to EAE. EAE is a mouse model of 
human MS, featured by demyelination and axonal degeneration happening in the CNS. 
It should be noted that in the previous study, the CNS was not included in the multiple 
organs affected by autoimmunity in the absence of STAT5 (Snow et al., 2003). In 
general, to initiate EAE, myelin-specific T cells are activated in periphery, and gain 
access to the CNS where they are reactivated by APCs that present self-antigen. T cell 
activation induces the production for soluble mediators that attract the entry of 
myeloid cells, and together they cause inflammation and demyelination. Therefore, 
we raised several possibilities to explain the resistance to EAE in Stat5-deficeint mice: 
first, Stat5 deletion impaired T cell response due to the role of STAT5 in mediating 
IL-2-induced T cell proliferation; second, unlike in vitro differentiation, loss of 
STAT5 dampened the generation of effector TH17 cells; third, the abrogation of 
STAT5 attenuated the migration of autoreactive T cells to the CNS; fourth, STAT5 
regulated a pathogenic mediator secreted by T cells to sustain neuroinflammation.  
Conditional targeting of STAT5 in T cells is reported to result in peripheral 
lymphopenia (Yao et al., 2006). This is probably due to the understanding that STAT5 
transmits IL-2 signal, which mediates T cell growth and proliferation. However, in the 
context of EAE, we didn’t observe any defect in CD4+ T cell activation. Comparable 
numbers of CD4+ T cells were detected in Stat5-deficient and control mice. It is 
possible that other signaling cascades mediate IL-2 signal and T cell proliferation. In 
this regard, MAKP and PI3K-Akt pathways are known to be activated by IL-2 
(Cacalano and Johnston, 1999). It is also possible that, under the pathological 
condition, proinflammatory cytokines promote CD4+ T cell growth and proliferation. 
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In this regard, IL-6 is reported to prevent apoptosis and promote proliferation of CD4+ 
T cells when IL-2 signaling is blocked (Takeda et al., 1998). The unaltered IL-2 
secretion further argues that the resistance to EAE in Stat5-deficeint mice is unlikely 
due to the impaired T cell activation.  
The antagonistic role of STAT5 in TH17 differentiation observed in vitro assays 
indicates that loss of STAT5 should not dampen the generation of effector TH17 cell 
during EAE development. It might be argued that in vivo and in vitro situations are 
different. Consistently, we showed an increased proportion of TH17 cell in the spleens 
of Stat5-deficient mice. In the inflamed CNS, the proportions of TH17 cells were 
comparable between Stat5-deficient and control mice. To explain inconsistency, it is 
notable that without exposure to IL-2, STAT5-deficeint cells exhibit the similar 
ability to generate TH17 as wild-type control. Furthermore, relative higher IL-6 
overcomes the suppressive effect of IL-2 in TH17 generation (Yang et al., 2011). Thus 
in the inflamed CNS, it is likely that proinflammatory cytokines dismiss the effect of 
IL-2. Both encephalitogenic TH17 and TH1 are able to initiate autoimmune 
neuroinflammation (Goverman, 2009). But the function of STAT5 in TH1 generation 
is still debated. Nevertheless, our data show TH1 generation is not dampened by Stat5 
deletion in the context of EAE. Collectively, we have demonstrated that although 
TH17 and TH1 generation is enhanced, Stat5-deficient mice are not susceptible to EAE 
induction.  
To initiate CNS inflammation, encephalitogenic T cells must gain access to the CNS. 
It has been proposed that CCR6-CCl20 axis facilitates the entry of a small amount of 
CCR6+ T cells into the CNS through choroid plexus and these infiltrating T cells 
initiate EAE (Reboldi et al., 2009). However, loss of STAT5 in T cells resulted in 
increased expression of CCR6 as well as CXCR3, a chemokine receptor for TH1 
migration. These data suggest that Stat5-deficient autoreactive CD4+ T cells are able 
to migrate to the CNS. Indeed, we detected comparable CD4+ T cell infiltration in 
Stat5 conditional mutant and control mice before disease onset. In the later stage, the 
reduced presence of CD4+ T cells in the CNS of Stat5 conditional mutant mice could 
be explained by the disability of Stat5-deficient CD4+ T to sustain neuroinflammation.. 
Our results argue that Stat5-deficient CD4+ T can migrate to the CNS but fail to 
induce EAE.  
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By excluding these possibilities, we therefore focused on characterizing the 
pathogenic mediator secreted by encephalitogenic CD4+ T cells, whose expression 
could be impaired by Stat5 deletion. 
 
Pathogenic mediator and IL-7-STAT5 signaling 
The major function of CD4+ helper T is mediated by the secretion of effector 
cytokines which orchestrate immune response. Although numerous studies have been 
tried to reveal the key effector T cell and real pathogenic mediator in EAE and MS, 
there are a lot of debates in this topic. TH1 is firstly described as the primary effecter 
T cell in the pathology MS, mostly because of the observation that the expression of 
IL-12 and IFN-γ in the CNS is associated with MS (Gutcher and Becher, 2007). In the 
EAE model, TH1 cells are also present inflamed CNS and, more convincingly, 
adoptive transfer of TH1 is able to induce EAE (Segal and Shevach, 1996). Given the 
association of TH1 and neuroinflammtion, this most unexpected finding is that 
IFN-γ-deficient mice are more susceptible to EAE development (Steinman, 2007). In 
addition, IL-12p35-deficient mice are also susceptible to EAE (Gran et al., 2002; 
Steinman, 2007). Paradoxically, IL-12p40 deletion protects mice from EAE (Gran et 
al., 2002). These findings argue that TH1 may not be the primary effector cell and 
IFN-γ may not be the pathogenic mediator.  
The realization that IL-12p40 subunit is shared by IL-12 and IL-23 indicates IL-23 
may play a key role in autoimmune neuroinflammation. Indeed, the view is proved by 
the finding that IL-23p19-deficient mice are resistant to EAE (Cua et al., 2003). 
Furthermore, Langrish and colleagues showed that IL-23 drove an IL-17-secresting T 
cell population highly pathogenic in autoimmune neuroinflammation (Langrish et al., 
2005). This IL-17-secreting helper T cell is further characterized as a novel subset 
distinct from TH1 and TH2 (Harrington et al., 2005; Park et al., 2005). Thus, it 
becomes intriguing to investigate the role TH17 in autoimmune diseases. In the past 
few years, intensive studies tend to support TH17 as the primary pathogenic T cell in 
autoimmune neuroinflammation (reviewed in Chapter 1.5). But a key question 
remains unsolved is what the pathogenic cytokine is in EAE and MS. TH17 produces 
feature cytokines IL-17, IL-17F and IL-22. Although IL-22 mediates IL-23-induced 
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dermal inflammation, it is not required for EAE (Kreymborg et al., 2007; Zheng et al., 
2007). IL-17 was previously thought as the pathogenic cytokine mediating 
neuroinflammation (Komiyama et al., 2006). But Haak et al argued that neither IL-17 
not IL-17F vitally contributed to EAE development (Haak et al., 2009). Our data 
show that Stat5-deficient CD4+ T cells possess enhanced IL-17 production but 
impaired encephalitogenicity, thus do not support IL-17 as a pathogenic mediator in 
EAE.  
Recently, GM-CSF is reconsidered for its role in autoimmunity. GM-CSF has been 
well known as a hematopoietic and proinflammatory cytokine. Due to the multiple 
cellular sources of GM-CSF, the role of T cell-specific GM-CSF in autoimmunity was 
not clear previously. Ponomarev et al. originally reported that only the T cell-specific 
production of GM-CSF was mandatory for EAE (Ponomarev et al., 2007). The 
finding that GM-CSF is induced by IL-23 further established GM-CSF as the real 
pathogenic mediator secreted by TH17 cells in EAE development (Codarri et al., 2011; 
El-Behi et al., 2011). We therefore decided to examine GM-CSF expression by 
Stat5-deficient CD4+ T cells. GM-CSF expression in the CNS was dramatically 
induced even before the onset of EAE, but was significantly attenuated in Stat5 
conditional deletion mice. The finding led us to hypothesize that STAT5 was required 
for optimal induction of GM-CSF in autoreactive CD4+ T cells, which was later 
demonstrated by our experiments. Then one direct question is what signal activates 
STAT5 to induce GM-CSF expression. Neither IL-23 nor IL-1β appears to potently 
activate STAT5, although both cytokines are required for EAE induction. We found 
IL-7 can strongly activated STAT5, implying a potential role of IL-7 in inducing 
GM-CSF expression.  
Our speculation is consistent with the previous reports that IL-7 is necessary for EAE 
induction (Liu et al., 2010; Walline et al., 2011). Intriguingly, IL-7Rα has been 
characterized to be associated with MS in humans (Gregory et al., 2007; Lundmark et 
al., 2007). But how to connect IL-7 signaling with MS pathology remains unclear. Liu 
et al. claimed IL-7 promoted TH17 expansion, which was dependent on STAT5 
activation (Liu et al., 2010). But Lee et al. argued that IL-7 signaling had not effect on 
TH17, but instead it enhanced TH1 response in EAE (Lee et al., 2011). However, in 
our study, conditional Stat5 deletion mice showed no defect in either TH17 or TH1 
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generation during EAE, arguing that the IL-7 mediates EAE unlikely through 
conventional TH17 or TH1 cells. Our results, for the first time, demonstrate that the 
pathological role of IL-7 in EAE and MS probably attributes to the induction of 
GM-CSF. Given the differential regulation of GM-CSF and IL-17 expression by 
STAT5, our data also indicate that GM-CSF-expressing TH could be the primary 
effector in EAE.  
Both IL-23 and IL-7 are necessary for EAE development. IL-23 can induce both 
IL-17 and GM-CSF expression in TH17 cells. But we showed the IL-7 induced 
GM-CSF expression independent of IL-17 expression. So, what is the relationship 
between TH17 and GM-CSF-expressing TH? How do IL-23 and IL-7 regulate EAE 
development, independently or synergistically? We found that the dramatic increase 
of GM-CSF expression in the CNS preceded IL-23 induction. The activation of TLR 
signaling is previously reported to induce an increase of serum IL-7, which further 
regulated T cell response (Sawa et al., 2009). On the contrary, IL-23 is produced by 
CNS-resident cells to control T cell encephalitogenicity in the effector phase of EAE 
(Becher et al., 2003). Based on current knowledge, we proposed a model to explain 
EAE development: self-antigen immunization induces IL-7 expression, which drives 
the generation of GM-CSF-expressing TH cells with high pathogenicity; 
GM-CSF-expressing TH cells migrate to the CNS and get reactivated by residual 
APCs to secret GM-CSF, which can recruit myeloid cell infiltration and induce IL-23 
expression; IL-23 reinforces GM-CSF expression by T cells to sustain 
neuroinflammation forming a positive feed-back loop (Fig. 25). However, much more 
work has to be done to test the model.  
 
GM-CSF-expressing TH: a new subset? 
Upon TCR activation by cognate antigen, CD4+ helper T cell differentiates to 
different lineages classified by three major criteria: cytokine milieu for lineage 
commitment, lineage-specifying transcription factor and effector cytokine being 
secreted. The differential regulation of IL-17 and GM-CSF expression by STAT5, and 
the presence of GM-CSF+IL-17- helper T cell led us to investigate whether 
GM-CSF-expressing cell could be a novel TH subset.  
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When naïve CD4+ T cell is committed to one specific lineage, the fates of other 
lineages are usually suppressed. IL-12, for instance, drives TH1 differentiation, but 
also inhibits TH1 and TH17 differentiation. The finding that either TH1- or 
TH17-polarizing conditions actually suppressed GM-CSF expression strongly argues 
that GM-CSF-expressing TH is an independent subset requiring different polarizing 
condition. Furthermore, IL-6-STAT3 signaling, a pathway crucial for TH17 
differentiation, strongly suppressed GM-CSF expression. It is likely that IL-7 is one 
of the cytokines that drive GM-CSF-expressing TH differentiation, given naïve CD4+ 
T cell expresses IL-7 receptor. We indeed showed that IL-7 promoted naïve CD4+ T 
cells differentiation into GM-CSF+ cells, with no IL-17+ or a few IFN-γ+ cells 
detected. STAT5 transmits IL-7 signal and thus is identified as a transcription factor 
for GM-CSF-expressing TH differentiation in our study.  
IL-23 is required for the terminal differentiation of TH17 and is believed to endow 
TH17 with pathogenicity. However, in EAE model, the pathological role of IL-23 
most likely attributes to GM-CSF induction. IL-23 is unlikely to act on naïve CD4+ T 
cells due the lack of its receptor. It is possible that IL-23 is required for stabilizing 
GM-CSF expression in the new subset programmed by IL-7-STAT5 signaling. But 
we don’t know how IL-23 exactly executes its function at this moment.  
Our study contributes to the current knowledge of helper T cell classification, but also 
further strengthens the concept of lineage plasticity. For instance, we observed the 
presence of IL-17+GM-CSF+ and IFN-γ+GM-CSF+ helper T cells in the EAE model. 
IL-23 can induce the expression of both IL-17 and GM-CSF. Probably the fates of 
helper T cell lineages are not as rigid as we previously thought. In this regard, “subset” 
may be better than “lineage”.  
 
Future directions 
We showed that Stat5-deficient CD4+ T cells lacked encephalitogenicity due to the 
impaired induction of GM-CSF. We further demonstrated that IL-7 activated STAT5 
and induced the generation of a novel TH subset, which abundantly produced 
GM-CSF and played a critical role in autoimmune neuroinflammation. However, 
several important questions remain to be further addressed: 
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1) What is the specificity of this novel TH subset?  
CD4+ T cells are classified into at least five subsets (TH1, TH2, TH17, iTreg and TFH) 
based on three major criteria: cytokine milieus for differentiation, lineage-defining 
transcription factors and cytokine production pattern (with details discussed in 
Chapter 1.3). The biological functions of different TH subsets are closely related to 
their cytokine production.  
GM-CSF used to be considered as a TH1 or TH17 cytokine. However, either TH1- or 
TH17-related cytokines suppress GM-CSF expression as demonstrated in this thesis. 
The CD4+ T cells featured by GM-CSF production may represent a novel subset 
distinct from any currently known TH subset. We have identified IL-7 as an important 
cytokine for the differentiation of this new subset, in parallel with IL-12 for TH1, IL-4 
for TH2, TGF-β and IL-6 for TH17. We further know STAT5 is the molecule 
transmitting IL-7 signaling and directly activating GM-CSF expression, just like 
STAT4, STAT6 and STAT3 transmitting IL-12, IL-4 and IL-6 signaling respectively. 
T-bet, GATA3 and RORγt are the master regulators defining TH1, TH2 and TH17 
lineages respectively. However, we haven’t found out the counterpart molecule in the 
new subset yet. Whether there is such a “master regulator” requires further 
investigation.  
GM-CSF is a feature cytokine of this new subset, but is there any other cytokines 
specifically expressed? TH1 cells express a unique cytokine pattern including IFN-γ, 
TNF-α and Granzyme B. whereas IL-4, IL-5 and IL-13 are specifically expressed in 
TH2 cells. For TH 17 cells, IL-17F, IL-21 and IL-22 are also abundantly expressed 
besides the unique cytokine IL-17. Thus, it is likely that this new subset of TH cells 
have other preferentially expressed cytokine. We will study this question in future 
work.  
To address these questions raised above, we will perform the microarray or RNA-Seq 
to map the transcript profile of different subsets, including naïve CD4+ T cells, TH1, 
TH2, TH17 and the new GM-CSF-expressing subset. Those genes preferentially 
expressed in this new subset will be further analyzed with focus on cytokines, 
transcription factors and chemokine receptors. This experiment will also provide 
useful information on how specific this new subset is.  
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2) Is this new subset of TH cells more pathogenic than others in neuroinflammation? 
Both TH1 and TH17 cells participate in autoimmune neuroinflammation. Currently, 
one relatively popular view is that TH17 cell are more important to drive the onset of 
this disease in the early stage, whereas TH1 cells play a major role in the later stage. 
However, none of feature cytokines secreted by either TH1 or TH17 cells is 
indispensible for EAE development. By now, GM-CSF is the only essential cytokine 
produced by autoreactive CD4+ T cells for EAE development (see Chapter 1.5). Our 
new subset of GM-CSF-expressing TH cells produce highly abundant GM-CSF 
compared with TH1 and TH17 cells. Thus, it is anticipated that this new subset is more 
pathogenic in neuroinflammation. We will work on this question in future work. 
3) How is the encephalitogenicity of autoreactive CD4+ T cells regulated by IL-7 and 
IL-23? 
Both IL-23 and IL-7 are essential mediators for autoimmune encephalomyelitis 
(Becher et al., 2003; Cua et al., 2003; Walline et al., 2011). Notably, IL-7α is highly 
related to MS in humans (Gregory et al., 2007; Lundmark et al., 2007). IL-23 
mediates terminal differentiation of the TH17 subset of helper T cells and the presence 
of the IL-23 receptor on T cells facilitated infiltration of TH17 cells into the CNS 
(Gyulveszi et al., 2009; McGeachy et al., 2009). IL-23 is more likely to play a crucial 
role in the effector phase of EAE development (Becher et al., 2003; Cua et al., 2003). 
Recently, it is proposed that the key function of IL-23 in EAE development is to 
induce GM-CSF expression in autoreactive CD4+ T cells, which can sustain 
neuroinflammation via activating microglia and recruiting myeloid cells into the CNS 
during the disease effector phase (Codarri et al., 2011; El-Behi et al., 2011). It is also 
known that naïve CD4+ T cells don’t express the receptor for IL-23. Therefore, it may 
conclude that IL-23 acts on autoreactive CD4+ T cells in the later stage of EAE 
development (effector phase) and is unlikely to play a role in driving naïve CD4+ T 
cells differentiation in the early stage.   
It is thought that GM-CSF endows TH17 cells encephalitogenicity. However, our 
study demonstrates that GM-CSF-expressing T cells could be a separate subset 
independent of TH1 or TH17 (see Chapter 6). Unlike IL-23, IL-7 can directly act on 
naïve CD4+ T cells to drive their differentiation into this new subset, which may 
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represent the primary encephalitogenic population in autoimmune neuroinflammation. 
Then several questions need to be addressed: Where does IL-7 play its function, in the 
spleens, LNs or CNS? What is the cellular source of IL-7? Is IL-7 constitutively 
expressed or inducible in autoimmune neuroinflammation?  
Given IL-23 is essential in EAE, one key question is how to link IL-23 to the new 
subset of TH cells? We found that the induction of GM-CSF preceded IL-23 induction 
in the CNS (Fig. 22). Based on current information, we propose a possible working 
model: IL-7 drives the generation of antigen-specific GM-CSF-expressing TH cells in 
periphery, which migrate to the CNS and induce IL-23 expression by APCs; IL-23 in 
turn acts on these T cells to reinforce GM-CSF expression and sustain 
neuroinflammation (also see Fig. 25). We will perform experiments to examine this 
hypothesis. . 
4) Is the fate of this new subset rigid or plastic (fate plasticity)? 
We found GM-CSF was co-expressed by IL-17+ and IFN-γ+ T cells in vivo. This is 
similar to many examples of TH cell plasticity where small populations of cells 
express cytokines of more than one subset (O'Shea and Paul, 2010). It is interesting to 
study whether differentiated GM-CSF-expressing TH cells are stable when exposed to 
different environmental cytokines, such as IL-12 or IL-6. Furthermore, this subset of 
TH cells might “reprogramme” to another population, such as TH1 or TH17, under 
certain conditions. A GM-CSF-GFP reporter strain of mice would be useful in long 
term. 
5) What is role of this new subset of TH cells in other autoimmune diseases?  
In this thesis, we have demonstrated that this new subset of TH cells is important for 
autoimmune neuroinflammation, but may be dispensable for T cell transfer colitis 
(Chapter 6). TH17 as an inflammatory T cell population participates in a variety of 
autoimmune diseases and inflammatory disorders. For instances, IL-17-deficient mice 
are resistant to collagen-induced arthtitis and IL-22 mediates IL-23-induced dermal 
inflammation (Nakae et al., 2003; Zheng et al., 2007). Defined as a new subset, the 
biological functions of GM-CSF-expressing TH cells remain largely unknown. We 
will develop new autoimmune disease models, for example experimental autoimmune 
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uveitis (EAU) and experimental autoimmune myocarditis (EAM), to explore more 
biological functions of this new subset.  
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